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ABSTRACT 
 This dissertation analyzed spatial agglomeration economies associated with the 
geographical distribution of the U.S. biotech industry. Three location issues associated 
with the biotech industry were addressed in the study. The first study utilized a Bayesian 
spatial tobit model and examined the overall and regional differences in factors affecting 
the location of the U.S. biotech industry. The second study examined the inter- and intra-
industry spatial association of biotech related research and development (R&D) and 
testing facilities across all contiguous U.S. counties employing a Spatial Two-Stage Least 
Squares model. Finally, the interdependence between different subsectors of the U.S. 
biotech industry was analyzed using a Seemingly Unrelated Regression model. 
The first study confirmed the hypothesis of spatial agglomeration for the spatial 
structure of the biotech industry, indicating that biotech firms are positively correlated 
across counties, resulting in clustering of biotech production. Availability of venture 
capital firms, research institutions, and hospitals were found to have the most significant 
impact on the location of biotech firms. Results from regional models indicate that 
biotech firms willing to locate in the West prefer to establish in metro-counties with easy 
access to research institutes and skilled labor pool. Conversely, firms that are willing to 
locate in the Northeast prefer counties with easy access to funding sources and hospitals 
for research, testing and marketing of new biotech products. 
Spatial clustering of biotech research and testing activities was confirmed in the 
second study. Proximity to manufacturing firms and research universities, and availability 
of venture capital firms were found to have the most significant impact on the location of 
R&D and testing facilities. Results indicated that public as well as private spillovers are 
at work in the R&D and testing industry, resulting in their spatial clustering.  
Agricultural biotechnology firms’ preference to locate in counties with large 
farmland, low median housing values and average hourly wage, and a high 
ix 
 
unemployment rate was indicated in the third study. Conversely, results indicate that 
firms belonging to drug and pharmaceuticals, and medical devices and equipment 
subsectors prefer to locate in counties with high standards of living and in close 
proximity of research institutes and hospitals to access skilled-labor, and develop and test 
new drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
Over the past few decades, state and local planners as well as spatial and 
economic scientists have been interested in understanding the forces that contribute to the 
clustering of innovative activities and growth potential of firms and regions.  A 
significant body of industry location literature focuses on economic externalities 
(technical and pecuniary externalities) and knowledge spillovers to analyze the reasons 
behind industry clusters (for recent review see Xia and Buccola, 2005; van Oort, 2004; 
Zuker, Darby, and Armstrong, 2003; Feldman, 2003; and Goetz and Rupasingha, 2002). 
Barkley and Henry (2001) defined industry cluster as “a loose, geographically bounded 
collection of similar and/or related firms that together create competitive advantages for 
member firms and the regional economy.” In general, there are two types of industry 
clusters: intra- and inter-industry clusters. The concept of intra-industry clusters is 
associated with the collaboration of firms of the same industry that utilize similar 
technologies and face common problems. These firms tend to share information on a 
broad variety of issues from problem solving to the development of new production 
techniques (Lall, Koo, and Chakravorty, 2003). Conversely, inter-industry clusters are 
associated with collaboration of firms between different industries that are connected 
through buyer-supplier chains or shared factors (Lall, Koo, and Chakravorty, 2003). 
Scorsone (2002) classified industrial clusters into two types: one is Value Chain, which 
include groups of businesses that buy and sell from each other, and the second is Labor 
Pool, where clusters are based on occupational categories. One of the main reasons for 
the formation of industry clusters is to lower the overall transaction costs associated with 
the production, marketing, and distribution of outputs (Porter, 1990). According to 
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Barkley and Henry (2001), the advantages of industrial clusters are that they strengthen 
localization economies, facilitate industrial reorganization, encourage networking among 
firms, and permit greater focusing of public resources. However, the authors also point 
out some of the shortcomings with industrial clusters which include difficulty in 
identifying the targeted industry, competitive advantage of early clusters over latecomers, 
and difficulty in establishing supportive institutions. Some of the other disadvantages 
with industrial cluster development are that they tend to increase local land rents, wages, 
congestion, and utility costs, eventually diverting new firms away from the region.  
 While several studies have analyzed the role of agglomeration forces (economic 
externalities and knowledge spillovers) on industry location, not much is yet understood 
on the spatial extent of agglomeration. First of all, we want to know whether the 
agglomeration forces are significant in the location of an industry or not, and if 
significant, how far (distance) are they effective? It is critical to analyze the concept of 
agglomeration forces based on space, distance and spatial dependence (van Oort, 2004). 
Data obtained from points in space are generally associated with spatial dependence and 
heterogeneity. The concept of spatial dependence is a functional relationship between two 
locations, indicating that what happens at one point in space is determined by what 
happens elsewhere in the system (Kaliba, 2002). This spatial dependence is considered to 
decrease as the distance between the points increase. In terms of the agglomeration 
forces, economies of scale associated with a firm located in a neighboring (contiguous) 
county are supposed to be greater as compared to other firms located in non-neighboring 
counties. The second issue related to spatial data is spatial heterogeneity, which deals 
with variation in relationships over space (LeSage, 1999). Neglecting these spatial 
concepts in econometric modeling will result in biased estimates, leading to erroneous 
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interpretation and wrong conclusions (Anselin, 1988; LeSage 1999).  This indicates that 
it is important to take into account spatial dependence and heterogeneity when analyzing 
the affects of agglomeration economies on industry location. Generally speaking, most of 
the previous studies on industry location have failed to incorporate spatial components in 
their econometric modeling (for recent exceptions see Roe, Irwin, and Sharp, 2002; 
Goetz and Rupasingha, 2002; Isik, 2004; van Oort, 2004; and Sambidi and Harrison, 
2005). 
  The biotech industry, which is one of the fastest growing industries in the 
U.S.(Biotechnology Industry Organization (BIO), 2005), provides us with an opportunity 
to analyze the spatial concepts of industry location. It has all the necessary characteristics 
for a thorough understanding of the growth of a new industry. These characteristics 
include: i) the industry being in its early stages of development, ii) association of biotech 
firms in intra- and inter-industry clustering, and iii) the industry’s uncertain future 
development in terms of locating new biotech firms (Feldman 2003).  
1.1 The U.S. Biotech Industry Facts 
The biotech industry is defined as “the application of biological knowledge and 
techniques to develop products and services” (BIO 2005). Goetz and Morgan (1995) 
defined it as “any technique that uses living organisms to make/modify products, improve 
plants or animals, or develop microorganisms for a specific use.” Biotech firms are 
mainly research and development (R&D) oriented and operate in collaboration with 
research-oriented universities, biomedical research centers, and  other diversified 
companies that aid in the production and distribution of biotech products. Biotech 
products may be characterized as drugs and pharmaceuticals, agricultural, and 
environmental, which aid in improving the quality of health, increasing the production of 
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agricultural goods, improving food quality, minimizing environmental hazards and 
providing a cleaner environment. 
  The biotech industry, which emerged during 1973 (Feldman, 2003), is one of the 
fastest growing industries in the United States, with increasing sales from $7.7 billion in 
1994 to $33.3 billion in 2004 (Ernst and Young, 2005). According to the BIO (2005), in 
2003 there were 1,473 biotechnology companies in the U.S., employing 198,300 people 
and spending $17.9 billion on research and development. The top five states in terms of 
number of biotech companies are: California (420), Massachusetts (193), North Carolina 
(88), Maryland (84), and New Jersey (77) (Ernst and Young, 2004). The biotech industry 
is mainly concentrated in nine cities/regions (San Francisco Bay Area, 
Boston/Cambridge, San Diego, Los Angeles, New York, Philadelphia, Raleigh-Durham, 
Seattle and Washington, DC), which account for three-fourths of the nation’s largest 
biotechnology firms and for three-fourths of the biotech firms formed in the past decade 
(Cortright and Mayer, 2002).   
  As a result of the increasing success of the biotech industry, several state and 
local economic development agencies are designing and implementing strategies to 
attract new biotech firms, resulting in stiff competition among and within states.  For 
example, in 2004, 40 states have adopted strategies to stimulate the growth of 
biotechnology and 50 states have technology based economic development initiatives for 
biotech firms, compared to merely 14 states in 2001 (Battelle and State Science and 
Technology Institute (SSTI), 2004).  A survey of 77 local and 36 state economic 
development departments indicated that 83% have listed biotechnology as one of the top 
two targets for industrial development (Grudkova, 2001; Cortright and Mayer, 2002).  
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1.2 Problem Statement 
The rationale for concentration of the U.S. biotech industry in California and the 
Northeast has been attributed to proximity to highly research-oriented universities, 
research parks and laboratories, and well-developed infrastructure. However, our 
understanding of the spatial influence (spatial dependence and heterogeneity) on the 
intra- and inter-regional distribution of biotech establishments is anecdotal. Moreover, as 
a result of increased competition in attracting biotech firms and increasing commercial 
applications, the U.S. biotech industry is undergoing changes in its geographical 
distribution. For example, during 1991-2001, while the concentration of biotech firms in 
the top states increased slightly, the relative ordering of states changed with New Jersey 
dropping below Maryland and North Carolina in terms of the number of establishments 
(Feldman, 2003).  Moreover, a study conducted by McCandless (2005) indicated that 
Dallas, Houston, San Antonio, Memphis, Richmond, and Miami-Dade are making 
significant progress in becoming important biotech regions of the future.  
These changes in the spatial distribution of the biotech industry as a result of 
increasing commercial applications indicate that proximity to universities is no longer a 
sufficient condition to promote the biotech industry cluster (Feldman, 2003). Earlier, 
biotech firms were considered to locate close to universities with star scientists based on 
the observation that biotechnology discoveries are characterized by tacit knowledge, 
which is best communicated through face-to-face contact (Feldman, 2003).  However, as 
a result of technology advancements, even tacit knowledge is now considered to spread 
quickly (Toole, 2003; Feldman, 2003). In addition, the previous literature on the biotech 
industry location has not taken into consideration the extent of inter-industry spatial 
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clustering of biotech firms and research institutes. Analyzing this will improve our 
understanding of the scale of spatial dependency of biotech firms on research institutes.  
The geographical changes in the biotech industry may also be attributed to other 
location factors. Generally speaking, the location decision is always associated with 
trade-off between location factors to lower the costs associated with procuring raw 
materials and producing and distributing the final product. In order to analyze the 
importance of trade-offs between location factors, let us briefly discuss the case of the 
U.S. broiler industry (mature industry), which has undergone a drastic change in its 
geographic distribution (Sambidi and Harrison, 2005). During the 1940s, the broiler 
industry was mainly concentrated in the Midwest, which has the advantage of low cost 
feed ingredients and low product transportation cost to large Midwestern cities. However, 
as a result of increasing land costs and wages in the Midwest, the broiler industry started 
to move to the South, which is associated with low land and labor costs. This movement 
also benefited from low rail rates associated with transporting feed from the Midwest to 
South. Currently, 85% of the U.S. broiler production is concentrated in the South 
(Sambidi and Harrison, 2005), thus indicating the significance of trade-offs between 
factors in industry location-decision. This typical example may open some doubts on the 
future of the spatial distribution of the biotech industry, since it is still at an early stage of 
development, and we have already started to see some geographical changes in its 
location. In addition, the current biotech locations are associated with congestion and 
high land, labor, and utility costs, prompting biotech companies to look for other sites 
with a comparatively more space and less costs (Munroe, Craft, and Hutton, 2002). 
Therefore, it is critical to analyze other location factors and resource endowments that 
may pull biotech firms away from research institutes. Additionally, it is also important to 
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analyze the statistical implications of the spatial clustering of biotech firms, which was 
ignored by earlier studies (except Goetz and Rupasingha, 2002). 
1.3 Justification 
The present study focuses on spatial economies (geographically determined 
externalities) associated with county-level biotech establishments. Involving spatial 
component in the biotech industry location analysis will aid in capturing important 
intangible aspects concerning spatial dependence and heterogeneity, which was not 
acknowledged by most of the previous studies. This spatial analysis will also aid in 
identifying some of the intermediate industries (such as research institutes, hospitals, and 
venture capital) that may cluster with the biotech industry and aid in the production of 
biotech products. It also helps in measuring the extent of intra- and inter-industry 
clustering, indicating the range of correlation among biotech firms and between biotech 
firms and other intermediate industries. Moreover, the spatial analysis also involves 
estimating the regional differences in factors affecting the location of the U.S. biotech 
industry. Analyzing these spatial concepts and location factors will aid state and local 
economic development agencies in designing strategies to better retain and attract biotech 
firms and their clusters, which in turn will boost their economy and provide employment 
opportunities for local residents.  
1.4 Research Question 
The primary question this study seeks to address is: how do factors such as 
localization economies, poverty, unemployment rate, population, median household 
income, median housing value, property tax, crime index, education, agricultural 
production, and proximity to venture capital firms, colleges, and hospitals affect the 
location of the U.S. biotech industry? The specific question this study seeks to address is: 
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do spatial agglomeration economies (spatial externalities and knowledge spillovers) exist 
in the location of biotech industry? If they exist: does it spillover predominantly between 
firms within the biotech sector or between firms in different sectors? And, what is the 
scope of spatial autocorrelation and correlation between firms within the biotech sector 
and between firms in different sectors, respectively?  
1.5 Objectives  
 The primary objective of this paper is to identify county level determinants of the 
spatial distribution of the U.S. biotech industry. Some of the specific objectives are:  
1) Analyze the extent to which numerous firm-specific, location-specific, and inter- and 
intra-industry spatial agglomeration factors affect the location, movement and 
concentration of the U.S. biotech industry.  This objective is achieved by utilizing a 
Bayesian spatial tobit model that captures the spatial organization of the biotech industry 
utilizing county-level data for the U.S.  
2) Examine the regional differences in factors affecting the location of the U.S. biotech 
industry. This objective is achieved by utilizing a separate Bayesian spatial tobit model 
for each of the U.S. census regions.  
3) Analyze the interdependence between different subsectors of the U.S. biotech industry. 
This objective is achieved by employing a Seemingly Unrelated Regression (SUR) and 
Spatial 2 Stage Least Square (Spatial 2SLS) model.  
4) Evaluate the presence and extent of intra-industry and inter-industry spatial 
correlation. This objective is achieved by utilizing Global Moran’s I Statistic and Local 
Indicators of Spatial Association (LISA) statistics. 
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1.6 Outline of the Dissertation 
This study accomplishes the four objectives through a ‘journal-article-style’ 
dissertation, given in chapters 3, 4, and 5. Chapter 2 includes a summary of industry 
location theory and a review of previous work. In chapter 3, the spatial clustering of the 
U.S. biotech Industry is presented. Spatial clustering of innovative activities, a case of 
U.S. biotech related research and testing activities is presented in chapter 4.  In chapter 5, 
the geographical distribution of biotech related manufacturing and Research & 
Development facilities in the U.S. is analyzed. Finally, an overall summary is included in 
chapter 6.  
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  CHAPTER 2 
REVIEW OF INDUSTRY LOCATION THEORY 
2.1 Introduction 
 The purpose of location theory is to determine the reasons for and explain why a 
particular factor is important to one industry and not to another (Greenhut, 1982). It also 
involves the principle of substitution, where an industry selects a site from alternative 
locations, which in terms of the economic theory, is similar to the problem of substituting 
labor for capital or land and vice versa  (Greenhut, 1982). Numerous factors are 
considered when determining a suitable site location for a firm. These factors vary 
depending on the particularities of an industry, but many factors associated with site 
selection are tied to finding the least-cost location of procuring raw materials and 
producing and distributing the final product.  
Generally speaking location theory is broadly divided into three theoretical 
schools (Brülhart, 1998), which include: 1) Neo-classical theory, 2) New trade theory, 
and 3) New Economic Geography (NEG). Since we are interested in industry location 
within the U.S., we will only discuss the first and the third theoretical schools. Neo-
Classical theory deals with the early stages of economic development before the 
industrial revolution, and is characterized by perfect competition, homogenous products 
and non-increasing returns to scale (Brülhart, 1998). This theory indicates that the 
location of an industry is determined exogenously, by the so called first nature (term used 
by Cronon (1991) and Krugman (1993a)), which indicates a given spatial distribution of 
natural endowments, climate, technology, and factors of production. Conversely, in the 
NEG theory, location is determined endogenously, by second nature (term used by 
Cronon (1991) and Krugman (1993a)), where spatial distribution of economic activities is 
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independent from natural advantage (Ottaviano and Thisse, forthcoming). The concept of 
second nature is characterized by mobility of production factors and/or firms, pecuniary 
and technical externalities, and input-output linkages (Brülhart, 1998). In the 
geographical economics, second nature is analyzed as the component of spatial 
conditional variation of economic activities that cannot be explained in terms of first 
nature, which is considered to be a control variable associated with natural advantage 
(Ottaviano and Thisse, forthcoming). It is this concept of second nature that leads to 
several theories on industrial location, which are grouped under the so-called New 
Economic Geography (NEG). NEG has been pioneered by Fujita (1988), Krugman 
(1991a, b, 1993b), and Venables (1996). As mentioned earlier in the NEG, location is 
determined by factor mobility, pecuniary and technical externalities, and input-out 
linkages, which in turn produce self reinforcing agglomeration processes (Brülhart, 
1998). These agglomeration forces will result in clustering of firms/industries, which 
further result in intra-inter industry specialization, as well as regional specialization.  
These concepts of the NEG theory have been discussed in the work of early economic 
geographers and location theorists such as von Thünen (1826), Weber (1909), Marshall 
(1920), and Hoover (1948). However, the important contribution of the recent economic 
geographers is that they all use general equilibrium models with monopolistic 
competition to explain the spatial variation of economic activities, making the concepts 
more acquiescent to empirical scrutiny and policy analysis (Ottaviano and Thisse, 
forthcoming).  
To better understand location theory, this study presents the location theories of 
leading writers as explained by Greenhut (1982). Examination of these writings will build 
a framework to better understand the rationale behind the biotech industry location 
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decisions. Since the U.S. biotech industry is mainly concentrated in the urban areas, we 
begin with von Thünen’s location theory, which emphasizes the concept of spatial 
heterogeneity in industry location.  von Thünen’s theory of location is based on 
evaluating tradeoffs between product-specific transportation costs and location-specific 
land rents. He developed a model to predict the type of agricultural product to be grown 
on geographically dispersed plots of land.  Key assumptions of the model include 
homogeneity of all land attributes except for its distance to a central market, i.e., the 
urban center. He assumes land is more valuable in the city relative to the country; 
implying land rents decrease the further away from the city a farm is located. This 
implies agricultural products grown on plots of land closer to the city are charged higher 
land rent relative to product grown further away from the city. On the other hand, 
products grown closer to the city are associated with lower transportation costs relative to 
product produced at a more distant location.  The type of product grown on a particular 
site is determined by selecting the type of production that yields the lowest cost, given 
tradeoffs between product-specific transportation costs and land rents.   
In contrast to von Thünen’s model, which assumes resources are given and the 
type of industry is chosen, Weber’s model assumes the type of industry is given and the 
optimal site is chosen.  Weber assumed that input supply and output demand are known, 
and there is an unlimited supply of labor at fixed locations at a given wage rate. He 
considered three general factors of location: transportation cost, labor cost, and 
agglomeration forces. When transportation cost is the only factor affecting the location of 
an industry, the site with lowest transportation cost will be selected. This site may be 
close to the output market, to the input market, or between input and output markets, 
depending upon the product.  Weber argued the orientation of industries is determined by 
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substitution between transportation and non-transportation cost factors, which include 
labor costs and agglomeration forces. This substitution involves non-transportation costs 
exerting a “locational pull”, where in some cases they attract an industry from the point 
of minimum transportation cost to a point of higher transportation cost. This change 
occurs as long as the savings in non-transportation cost factors exceed the additional 
transportation costs incurred. Though Weber’s location model is a general theory of 
location for all industries, his assumption of constant demand and omission of 
institutional factors such as  interest rate, insurance, taxes and others leaves gaps in the 
theory (Greenhut, 1982). 
Hoover’s theory of industry location bridges this gap by focusing on demand 
determinants as well as transportation and production factors. Hoover’s inclusion of 
institutional factors provides a more comprehensive theory of firm location than either 
von Thünen or Weber. Hoover argued that local property taxes were an important 
element of land cost, thereby influencing the location decision.  A distinguishing feature 
of Hoover’s theory is the introduction of fuel and raw material costs, agglomeration 
forces, and the costs generated by factors such as taxes and climate on the location 
decision.  
2.2 Industrial Clustering and the Economics of Agglomeration  
Over the past decade, industrial cluster development is gaining importance as the most 
vital strategy for economic development to enhance overall regional growth. Moreover, 
most of the state and local economic development agencies and research economists 
believe industrial cluster analysis as a policy solution for all regional problems (vom 
Hofe and Chen 2006). Akundi (2003) conducted a survey of state cluster initiatives and 
found that as many as 40 states in the U.S. consider industrial cluster analysis as their 
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critical strategy to promote economic development. Perroux (1950) proposed growth pole 
/ development pole theories to explain how industrial cluster aided in economic 
development. He argued that well-established firms in a region serve as catalyst (growth 
poles) to smaller firms in geographic proximity by spreading positive economic effects. 
Perroux believes economic space as conceptual and homogenous environment where 
firms buy from and sell to one another following centrifugal and centripetal forces. 
Perroux (1988) added time to his growth pole theory and indicated that economic 
development by industrial clusters involve two stages: a first stage involve clustering of 
business and firms, and in second stage growth spreads to other regions through the 
goods, investment and information (vom Hofe and Chen 2006).  
Agglomeration economies are considered to be one of the driving forces behind 
clustering of industries. Over the past few decades economic geographers and location 
theorists have analyzed different forms of agglomeration economies to better understand 
the theory behind industry location. The concept of agglomeration economies indicate 
that the performance of one firm is influenced by other firms located nearby. If a firm 
benefits by locating near an existing firm, it indicates positive economies of scale. 
Conversely, if a firm is deterred by locating near an existing firm, it indicates negative 
economies of scale. Agglomeration economies are further divided into Localization 
economies and Urbanization economies. Localization economies involve technical 
externalities and knowledge spillovers (Marshall-Arrow-Romer (MAR) externalities) that 
are specific to an industry whereby the productivity or growth of a firm in a given 
industry in a given region is assumed to increase the performance of others firms in that 
industry (van Oort, 2004). The externalities and spillovers include: the formation of a 
skilled labor pool and the production of new ideas (based on accumulation of human 
17 
 
capital and face to face communication) and the availability of specialized input services 
(Marshall, 1920; Ottaviano and Thisse, forthcoming). Urbanization economies reflect 
economic externalities that are transferred to firms of different industries as a result of 
savings from large scale operation of a city as a whole (van Oort, 2004).  It indicates 
economies of scale associated with generalized location factors such as good 
infrastructure, favorable community attitude, tax credits and subsidies, and favorable 
socioeconomic factors. These factors are not specific to a particular industry, but, favor 
any kind of industry. This in turn results in sectoral diversity, and that is why we see a 
wide variety of industries in major metropolitan areas. Chinitz (1961) argued that 
urbanization economies have a higher prospect of successful economic development than 
localization economies. According to him, established older cities act as an incubator that 
creates new firms, business and economic opportunities. The level of success for urban 
economic regeneration or continued development depends on the level of diversification 
of industrial cluster (Chinitz 1961; vom Hofe and Chen 2006). 
 van Oort (2004) analyzed several theories that were proposed to determine the 
performance of agglomeration economies on industry growth and innovation. The MAR 
theory which focuses on localization economies argues that knowledge spillovers are 
more important when there is little local competition, so that rents associated with sector-
specific knowledge can be internalized. Moreover, in terms of better growth, the theory 
favors local monopoly over local competition, as the former restricts the flow of ideas to 
other firms, and therefore allows innovator-internalization (van Oort, 2004). Conversely, 
Porter (1990), who also focuses on localization economies, argues that it is the local 
competition that favors rapid adoption of new technology, as different firms in an 
industry wants to capture as much market share as possible. Jacobs (1969) agrees with 
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Porter’s thought that local competition favors growth, but argues that regional diversity in 
economic activity (Urbanization economies) will result in higher growth  and innovation 
as knowledge and technical externalities resulting from one sector can be successfully 
adopted by other sectors (Van Oort, 2004). Scott (1988) argues that vertical disintegration 
is positively associated with geographical agglomeration.  According to the author, firms 
tend to cluster in territorial space in order to reduce the time and costs of transacting. 
2.3 Analytic Framework 
 The analytic framework to examine the location of the U.S. biotech industry 
stems from the New Economic Geography (NEG) literature, which stresses the 
importance of agglomeration forces in the formation of industry clusters. Fujita and Mori 
(2005) identified four key elements of NEG, which include: 1. general equilibrium 
modelling of spatial economy, which distinguishes NEG compared to other traditional 
location theories and economic geography; 2. increasing returns at the level of individual 
producers leading to imperfect competition; 3. transport costs, which is a key factor in 
firm location-decision, and 4. locational movement of producers and consumers leading 
to agglomeration economy (Fujita and Mori 2005). The core-periphery model (CPM), 
introduced by Krugman (1991a) provides a central framework of the NEG and illustrates 
the role of above mentioned key elements in changing the spatial structure of economic 
geography (Fujita and Mori 2005).  This study summarizes the CPM model as 
demonstrated by Fujita and Mori (2005). The basic structure of the CPM assumes that 
there are two initially symmetric regions (north and south), two production sectors 
(agriculture and manufacturing), and fixed endowments of two sector-specific factors 
(industrial workers and agricultural labors). Agricultural labors are not geographically 
mobile whereas industrial workers do migrate with response to the regional wage 
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differences.  The manufacturing sector produces horizontally differentiated product with 
scale economies where each firm producing a separate product utilizing workers as the 
only input. Conversely, agriculture sector produces a homogenous good under perfect 
competition and constant returns using only labor as input.  Both manufacture and 
agriculture goods are traded, but trade of manufactures involves positive transport costs. 
 There are two forces driving the spatial structure of the economy, the centripetal 
and centrifugal forces. The immobility of agricultural labor is considered as a centrifugal 
force as they consume both goods. The cause of centripetal force, however, is 
complicated. First, a region with more number of firms is considered to produce a large 
variety of goods. Workers in that region will have access to wide variety of goods, thus 
increasing their real income. As a result of this, workers from other region migrate 
toward the region with access to large variety of goods.  Secondly, as number of workers 
in a region increase, the market size of that region increases, inducing producers to 
concentrate in that region to benefit from scale economies and at the same time lower 
transport costs. This movement of workers to be close to producers of consumer goods 
(forward linkages) and the preference of producers to concentrate in a region with large 
market size (backward linkage) results in a centripetal force (Krugman 1991a; Fujita and 
Mori 2005). As a result of these centrifugal and centripetal forces, the economy exhibits a 
core-periphery pattern, turning one region into industrial core and the other into non-
industrial periphery (Krugman 1991a). This theory explains how locational movement of 
consumers and producers lead to an agglomerated economy.  
A firm/industry tries to locate close to other firms/industries in order to obtain 
positive economies of scale, thus resulting in intra- and inter-industry specialization 
(clusters). Spatial clustering is eventually limited by offsetting diseconomies such as high 
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land rent, wages, traffic congestion, and density-related pollution (van Oort, 2004). 
However, new firms still try to locate in close spatial proximity of the existing clusters in 
order to utilize economic externalities (Phelps, Fallon, and Williams, 2001). Therefore, it 
is important to incorporate agglomeration economies to measure the performance of an 
industry.  
 To analyze the location of the U.S. biotech industry, this study develops a location 
model based on drawing from Lall, Koo, and Chakravorty (2003), Fujita and Thisse 
(1996), and Fujita (1988). Let b(x, y, z) be the benefit (localization economies) obtained 
by a firm at x from a firm (same industry) located at y, which is at a distance z, from x. 
This benefit is assumed to be inversely proportional to the distance z, indicating that as 
the distance between two firms’ increases, economies of scale associated with the 
externalities decreases. Let  f(y) be the density (number) of all firms at each location y є 
X then, 
(2.1)    ∫=
X
dyyfzyxbxB )(),,()(  
where B(x) represents the aggregate benefit (in dollars) obtained by a firm at x from the 
externalities created in region X. As an aggregate term, the density of firms at each 
location, f(y), represent urbanization economies, which are external to industries and 
depend on overall scale as well as scope of economic activity in a given region, 
indicating inter-industry specialization (Lall, Koo, and Chakravorty, 2003). Thus, the 
aggregate benefit B(x) is a function of localization and urbanization economies, 
representing the overall agglomeration economies.  
 Assume that production utilizes land (K) and labor (L) with rents of R(x) and W(x) 
respectively at x, where x є X. Let TR(x) represent total revenue for a firm located at x 
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and let TC(x) represent the transportation costs incurred by that particular firm, which 
maximizes profits subject to: 
(2.2)   )()()()()( xTCLxWKxRxTRx −−−=Π  
    ),,),(()( lonxBpfxTR =  
Where p represents the vector of output prices, f (.) represents a function of quantity of 
output produced, n is the vector of inputs, o is the vector of outputs, and l is the vector of 
location factors other than agglomeration economies.  
2.4 Review of Spatial Econometric Modeling in Industry Location 
 Most of the previous empirical studies on industry location have employed non-
spatial econometric models, such as Ordinary Least Squares (OLS), Poisson, Negative 
Binomial, and Tobit  (for recent exceptions see Roe, Irwin, and Sharp,2002; Goetz and 
Rupasingha, 2002; Isik, 2004; and Sambidi and Harrison, 2005). Since the data are 
collected with reference to points in space, employing OLS (and models mentioned 
above) as an econometric tool will produce spatially autocorrelated residuals, resulting in 
biased estimates and all inferences based on the model may be incorrect (Anselin, 1988; 
LeSage, 1999). This section summarizes some of the spatial concepts associated with 
data collected from points in space and discusses issues related to its modeling. Spatial 
issues presented in this section are mainly derived from Anselin (1988) and LeSage 
(1999).  
 Data obtained from points in space are generally associated with spatial 
dependence and heterogeneity (Anselin 1988; LeSage 1999). Spatial dependence 
indicates that observations at a particular location depend on observations at other 
locations. This spatial dependence in some instances is also expressed as spatial 
autocorrelation (Anselin 1988). Conversely, spatial heterogeneity refers to variations in 
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spatial structure in the form of non-constant error variance or model estimates (Anselin 
1988). It indicates that relationship between sample data observations varies as we move 
across the space, thus violating Gauss-Markov assumption that a single linear relationship 
with constant variance exists across the sample (LeSage 1999). Alternative estimation 
procedures are required to deal with this variation and draw inferences.  Spatial 
econometrics is considered as the collection of techniques that deal with spatial issues 
(spatial autocorrelation and heterogeneity) in regression models that utilize data collected 
from points in space (Anselin 1988). Spatial econometric models include variables that 
account for spatial interaction within the data by employing a spatial weights matrix. 
2.4.1. Spatial Weights 
In the spatial literature, the spatial weight matrix provides the composition of assumed 
spatial relationships among different points in space. This matrix is utilized as a variable 
in econometric modeling to capture the spatial effects (spatial dependence and 
heterogeneity) within the data.  It is generally built based on the distance between spatial 
units or the contiguity between spatial unites. Generally speaking, spatial weights matrix 
that are based on contiguity include two values 0 and 1. If two spatial units share a 
common border then they are assumed to be connected and are given a value of 1 and 0, 
otherwise.  The weight matrix for three spatial units is represented as follows: 
(2.3) 
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where wij may be inverse distance between two spatial units (i and j)  or 0, 1 if they share 
a border and/ or vertex. The spatial weight matrix W is symmetric, and by principle it 
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always has zeros on the main diagonal (LeSage 1999). There are different types of 
contiguity based weights matrices as discussed by LeSage (1999): 
1. Linear contiguity: wij=1 for counties that share a common edge to the immediate right 
or left of the county of interest. 
2. Rook contiguity: wij=1 for counties that share a common side with the county of 
interest. 
3. Bishop contiguity: wij=1 for counties that share a common vertex with the county of 
interest. 
4. Double linear contiguity: wij=1 for two counties to the immediate right or left of  the 
county of interest. 
5. Double rook contiguity: wij=1 for two counties to the right, left, north and south of the 
county of interest. 
6. Queen contiguity: wij=1 for counties that share a common side or vertex with the 
county of interest. 
The spatial weights matrix is often standardized (row-sums to unity) and 
multiplied with a vector of observation y (dependent variable) in empirical work, where it 
is represented as a new variable (Wy) known as spatial lag variable. This variable is equal 
to the mean of observations of the dependent variable from contiguous counties (LeSage 
1999). This indicates that what happens at one point in space is function of what happens 
elsewhere, i.e. yi = f(yj), j # i (LeSage 1999). The linear relationship between the 
dependent variable and the spatial lag variable is expressed as follows: 
(2.4) ερ += yy W  
where ρ is a spatial autoregressive parameter, which represents the spatial dependence in 
the sample data. It measures the average influence of neighboring or contiguous counties 
24 
 
on counties in the vector y (LeSage 1999). A significant parameter ρ will indicate that the 
data under consideration is spatially dependent and employing OLS models will result in 
inconsistent and biased estimates.  
2.4.2 Spatial Econometric Models 
To overcome the problem of spatial dependence in standard linear regressions, 
two specifications are available: adding an explanatory variable in the form of a spatially 
lagged dependent variable, or in the error structure (Anselin 1988).  Spatial econometric 
model associated with the former specification is referred to as a spatial autoregressive 
model (SAR), which is appropriate when spatial dependence operates in the form of a 
spatially lagged dependent variable. The model with latter specification is referred as 
spatial error model (SEM), which is relevant when the spatial dependence operates 
through the disturbance term (Anselin 1988).  The SAR model is also referred as spatial 
lag model and is expressed as: 
(2.5)                                
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where y is a n x 1 vector of the dependent variable, Wy is a spatially lagged dependent 
variable for spatial weights matrix W, ρ is the scalar for spatial lag coefficient, β is the k 
x 1 parameter vector, X is the n x k matrix of exogenous explanatory variables, μ is an n 
x 1 vector of normally distributed error terms with zero mean and variance σ2. The spatial 
lag Wy can be considered as a spatially weighted average of the dependent variable at 
neighboring counties. This spatial lag term is assumed to be correlated with error terms, 
even though the later are independent and identically distributed (Anselin 1999). This 
relation is expressed as follows: 
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 Accordingly, the spatial lag should be considered and estimated as an endogenous 
variable; failing to do so will generate inconsistent and biased estimates for the parameter 
coefficients in the model (Anselin et al. 2000). The spatial lag coefficient ρ implies 
positive spatial correlation if ρ > 0, negative correlation if ρ < 0, and no correlation  
if  ρ = 0. 
 The second form of spatial dependence, which is often expressed as a spatial 
autoregressive process caused by the misspecification of error term (eg. omitted 
variables) is expressed as: 
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where ε represents non-spherical error terms expressing spatial dependence in the off-
diagonal elements of its covariance matrix,  λ is a spatial autoregressive coefficient and μ 
is a standard spherical error term.  Ignoring spatial dependence in the error term does not 
lead to biased estimates, but the estimate of their variance will be biased, leading to 
erroneous interpretations and wrong conclusions (Anselin et al. 2000). The spatial 
autoregressive coefficient indicates that error terms are positively correlated if λ > 0, 
negatively correlated if λ < 0, and not correlated if λ = 0. 
 If there was evidence indicating spatial dependence in both forms (spatial lag and 
error terms), a more general specification can be employed. This general spatial 
specification is called general spatial model (SAC), which accounts for both the spatially 
lagged term as well as a spatial error structure. The SAC model is represented as follows: 
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This specification is employed if there is evidence that spatial dependence existed in the 
error structure from a SAR estimation, which is tested by employing a Lagrange 
Multiplier test. Before estimating a spatial econometric model, the presence of spatial 
dependence in data can be analyzed utilizing spatial exploratory models, which are 
discussed in the following section. 
2.4.3 Spatial Exploratory Analysis 
2.4.3.1 Global Moran’s I 
The spatial association of data collected from points in space is tested using a Global 
Moran’s I, which measures similarities and dissimilarities in observations across space 
(Anselin, 1995). For the number of biotech establishments y, Moran’s I is: 
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where wij indicates elements of the spatial weight matrix W (distance/contiguity weight 
matrix) between two points (i & j), μ the mean of all y observations, and i, j=1,…,n. A 
positive and significant value for Moran’s I indicate positive spatial correlation, showing 
that counties have a high or low number of establishments similar to their neighboring 
counties. Conversely, a negative and significant value for Moran’s I indicates negative 
spatial correlation, showing that counties have high or low number of establishments 
unlike neighboring counties (Pacheco and Tyrrell, 2002). The study calculate’s Moran’s I 
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for the number of biotech establishments across all contiguous U.S. counties, employing 
GeoDa, a spatial data analysis software.   
2.4.3.2 Local Indicators of Spatial Association (LISA) 
In the case of uneven spatial clustering, global spatial indicators such as Moran’s I are 
found to be less useful. This resulted in a new general class of local spatial indicators 
such as Local Indicators of Spatial Association (LISA, also known as Local Moran), 
which measures the contribution of individual counties to the global Moran’s I statistic 
(Anselin, 1995).  The LISA statistic is calculated for the ith county as: 
(2.10)    ∑=
j
jijii zwzI  
where wij indicates elements of the spatial weight matrix W (distance/contiguity weight 
matrix) between two points (i & j), zi and zj indicates the standardized number of 
establishments for county i and j, respectively.  The sum of LISAs (∑
i
iI  ) for all 
observations is proportional to global Moran’s I, implying that LISA statistic can be 
interpreted as indicators of local spatial clusters and as diagnostics for local instability 
(spatial outliers) (Anselin, 1995).  
 The LISA cluster map indicates the locations with a significant Local Moran 
statistic classified by type of spatial correlation: (a) high-high association (HH), a county 
with many biotech firms has neighboring counties with many biotech firms; (b) low-low 
association (LL), a county with few biotech firms has neighboring counties with few 
biotech firms; (c) low-high association (LH), a county with few biotech firms has 
neighboring counties with many biotech firms; and (d) high-low association (HL) , a 
county with many biotech firms has neighboring counties with few biotech firms. The 
HH and LL locations suggests clustering of similar values (positive spatial correlation), 
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whereas the HL and LH locations indicate spatial outliers (negative spatial correlation) 
(Anselin, 1995). 
2.4.3.3 Multivariate Global Moran’s I  
In addition to the spatial autocorrelation, multivariate spatial correlation is also analyzed 
employing a multivariate Moran’s I statistic. The multivariate spatial correlation “centers 
on the extent to which values of one variable (zk) observed at a given location show a 
systematic (more than likely under spatial randomness) association with another variable 
(zl) observed at the neighboring locations.” (Anselin, Syabri, and Smirnov, 2002). The 
multivariate Moran’s I is as follows: 
(2.11)     
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where n indicates the number of observations, W indicates rook contiguity weight matrix, 
and zk and zl indicate standardized variables with mean zero and standard deviation equal 
to one (Anselin, Syabri, and Smirnov, 2002).  
2.4.3.4 Multivariate LISA 
Using a similar rationale as in the development of LISA, a Multivariate Local Moran 
Statistic (MLMS) was developed by Anselin, Syabri, and Smirnov (2002). This is defined 
as follows: 
(2.12)     jl
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where wij indicates elements of the spatial weight matrix, W (Rook contiguity weight 
matrix), and ikz  and 
j
lz  indicates the standardized variables for county i and j, 
respectively.  The MLMS “gives an indication of the degree of linear association 
(positive or negative) between the values for one variable at a given location i and the 
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average of another variable at neighboring locations.” (Anselin, Syabri, and Smirnov, 
2002). Similar to LISA, MLMS suggests two classes of positive spatial correlation, or 
spatial clusters (HH and LL), and two classes of negative spatial correlation, or spatial 
outliers (HL and LH) (Anselin, Syabri, and Smirnov, 2002). 
2.5 Conclusion  
This chapter briefly discussed different theories related to industry location. It developed 
an analytical framework that emphasizes the significance of agglomeration economies on 
the biotech industrial cluster development. It also argued some of the spatial issues 
associated with data collected from points in space and discussed suitable econometric 
models that successfully incorporate those spatial issues in modeling the location biotech 
industry.  The following chapter presents the spatial clustering of the U.S. biotech 
Industry. Spatial clustering of innovative activities, a case of U.S. biotech related research 
and testing activities is presented in chapter 4.  In chapter 5, the geographical distribution 
of biotech related manufacturing and Research & Development facilities in the U.S. is 
analyzed. 
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CHAPTER 3 
SPATIAL CLUSTERING OF THE U.S. BIOTECH INDUSTRY 
3.1 Background 
The biotech industry is defined as “the application of biological knowledge and 
techniques to develop products and services” (Cortright and Mayer, 2002; BIO, 2005). 
Goetz and Morgan (1995) defined it as “any technique that uses living organisms or parts 
of organisms to make/modify products, improve plants or animals, or develop 
microorganisms for a specific use.” Biotech firms are mainly research and development 
(R&D) oriented and operate in collaboration with research-oriented universities, 
biomedical research centers, and  other diversified companies that aid in the production 
and distribution of biotech products. Biotech products may be characterized as drugs and 
pharmaceuticals, agricultural, and environmental, which aid in improving the quality of 
health, increasing the production of agricultural goods, improving food quality, 
minimizing environmental hazards and providing a cleaner environment (Ernst and 
Young, 2005).  
The biotech industry is one of the fastest growing industries in the U.S., 
increasing sales from $7.7 billion in 1994 to $33.3 billion in 2004 (Ernst and Young, 
2005). According to the Biotechnology Industry Organization (BIO, 2005), in 2003 there 
were 1,473 biotechnology companies in the U.S., employing 198,300 people and 
spending $17.9 billion on research and development. The top five states in terms of 
number of biotech companies are: California (420), Massachusetts (193), North Carolina 
(88), Maryland (84), and New Jersey (77) (figure 3.1; Ernst and Young, 2004). The 
biotech industry is mainly concentrated in nine cities/regions (San Francisco Bay Area, 
Boston/Cambridge, San Diego, Los Angeles, New York, Philadelphia, Raleigh-Durham,  
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Figure 3.1. U.S. Biotech Companies by State and Province. 
 
 
Seattle  and Washington, DC), accounting for three-fourths of the nation’s largest 
biotechnology firms and for three-fourths of the biotech firms formed in the past decade 
(Cortright and Mayer, 2002).   
 As a result of the increasing success of the biotech industry, several state and 
local economic development agencies are pursuing strategies to attract new biotech firms, 
resulting in stiff competition among and within states.  For example, in 2004, 40 states 
have adopted strategies to stimulate the growth of biotechnology and 50 states have 
technology based economic development initiatives for biotech firms, compared to 
merely 14 states in 2001 (Battelle and State Science and Technology Institute (SSTI), 
2004).  Moreover, a survey of 77 local and 36 state economic development departments 
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indicated that 83% have listed biotechnology as one of the top two targets for industrial 
development (Grudkova, 2001; Cortright and Mayer, 2002).  
 As a result of increased competition in attracting biotech firms, the U.S. biotech 
industry is undergoing changes in its geographical distribution. For example, 
between1991 and 2001, the concentration of biotech firms in the top states increased 
slightly, but the relative ordering of states changed with New Jersey dropping below 
Maryland and North Carolina in terms of the number of establishments (Feldman, 2003).  
Moreover, a study conducted by McCandless (2005) indicated that Dallas, Houston, San 
Antonio, Memphis, Richmond, and Miami-Dade are making significant progress in 
becoming important biotech regions of the future. Therefore, it is critical to analyze the 
economic factors and resource endowments that may affect the location of biotech firms. 
Additionally, it is also important to analyze statistical implications of the spatial 
clustering of biotech firms, which was excluded in earlier studies (except Goetz and 
Rupasingha, 2002).  
 The primary objective of this paper is to identify county level determinants of the 
spatial distribution of the U.S. biotech industry. Specifically, this study analyzes the 
extent to which numerous firm-specific, location-specific, and inter- and intra-industry 
spatial agglomeration factors affect the location, movement and concentration of the U.S. 
biotech industry. The study utilizes a Bayesian spatial tobit model that captures the 
spatial organization of the biotech industry utilizing county-level data for the United 
States. Analyzing these factors will aid state and local economic development agencies in 
designing strategies to better retain and attract biotech firms, which in turn will boost 
state and local economies and provide employment opportunities for their residents.  
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3.2 Literature Review 
 Several studies have empirically examined the location aspects of the U.S. biotech 
industry (Goetz and Morgan, 1995; Darby and Zucker, 1996; Gray and Parker, 1998; 
Prevezer, 1998; Lerner and Merges, 1998;; Zucker, Darby, and Brewer, 1998; Brennan, 
Pray and Courtmanche, 1999; Zucker, Darby, and Armstrong, 2003; Xia and Buccola, 
2005). The rationale for concentration of the U.S. biotech industry in California and the 
Northeast has been attributed to proximity to highly research-oriented universities, 
research parks and laboratories, and well developed infrastructure. Gray and Parker 
(1998) examined the theoretical arguments surrounding the location and organization of 
biotech firms and analyzed the prospects for industrial renewal and regional 
transformation. The authors segregate the U.S. biotech industry into three different 
categories/regions based on the functions performed by biotech firms in those regions. 
The first category includes mature drug producing regions, such as New York, New 
Jersey, Pennsylvania, Delaware, Illinois, and Indiana. These regions include mature 
pharmaceutical firms that were established prior to the commercialization of 
biotechnology (before 1970s), and are now primarily involved in the manufacturing (53 
%) and marketing (72%) of new drugs. Another category includes emerging drug-
producing regions, such as San Francisco, San Diego, Los Angeles, Seattle, and Boston. 
Firms in these regions were established mainly during and after the commercialization of 
biotechnology, and are primarily involved in R&D activities (82%) for new drugs. A 
third category includes low-cost periphery regions, such as Puerto Rico, the Southern 
states of the U.S., and other scattered isolated rural areas.  Biotech firms in these regions 
undertake the production of drug products that have achieved commercial scale and other 
intermediate products (Gray and Parker, 1998).  
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Munroe, Craft, and Hutton (2002) conducted a survey of biotech companies in 
three California counties (Alameda, Contra Costa, and Solano). The results indicated that 
proximity to leading research centers (i.e. ready supply of skilled labor, access to ongoing 
research activities, new technology, etc.) as primary determinants for their current 
locations. Access to venture capital, a well-trained workforce, space for expansion and 
access to new technology were considered to be the most critical requirements for the 
growth and prosperity of respondents’ business. The results also indicated that state and 
local economic development agencies that provide financial assistance packages (i.e. 
subsidies, tax advantages, loan guarantees, etc.), biotechnology incubators/research parks 
(with appropriate zoning, infrastructure and public transportation), promote public 
awareness and training programs for the workforce are more likely to attract biotech 
firms. Other results indicated that some of the respondents were willing to locate in 
regions associated with lower costs (housing, space, wages, etc.), less 
congestion/commuting, and good incentives such as subsidies and tax credits (Munroe, 
Craft, and Hutton, 2002).                                                       
Goetz and Rupasingha (2002) analyzed the site-specific determinants of the U.S. 
high-tech industry, which includes firms that are involved in biotech activities, such as 
drug and pharmaceutical manufacturing firms and R&D services. Their results indicated 
that the availability of an existing high-tech firm, number of college graduates, local 
property taxes, population (urbanization economies), total county income, highway 
access, and county amenity scale have a positive and significant impact on the location of 
high-tech firms. Conversely, a county’s unemployment and unionization rate, per capita 
pollution, and the percentage of blacks were found to have a negative and significant 
impact on the high-tech firm’s location (Goetz and Rupasingha 2002). The present article 
differs from previous literature in that we examine the economies of scale associated with 
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county-level spatial agglomeration factors, exclusively for firms involved in the biotech 
activities. Moreover, our study includes several biotech related sub-industries 
(Agricultural Feedstock and Chemicals) that are of potential interest to agricultural 
research institutions.   
3.3 Data 
The biotech industry is a composition of numerous manufacturing, R&D, and services 
industries. Consequently, it does not have a separate NAICS code since different 
subsectors are involved in the production of biotech products. However, Battelle 
Technology Partnership Practice and State Science and Technology Institute (SSTI) 
(2004) classified the bioscience1 into five major subsectors as follows: 1. Agricultural  
Feedstock and Chemicals (NAICS: 311221, 311222, 311223, 325193, 325199, 325221, 
325222, 325311, 325312, 325314, 325320, 424910), 2. Drugs and Pharmaceuticals 
(NAICS: 325411, 325412, 325413, 325414), 3. Medicinal Devices and Equipment 
(NAICS: 339111, 339112, 339113, 339114, 334510, 334516, 334517), 4. Research and 
Testing (NAICS: 541380, 541710), and 5. Academic Health Centers, Research Hospitals, 
and Research Institutes. The first four subsectors include twenty five industries that are 
involved in biotechnology activities, with total employment of 885,368 jobs across 
17,207 establishments (Battelle and SSTI, 2004). Figure 3.2 illustrates the U.S. 
employment distribution across the bioscience subsectors.  
The present study analyzed several categories of variables that are considered to 
affect the location of biotech firms, such as agglomeration factors, infrastructure factors, 
and local economic and socioeconomic factors. County-level data was obtained from the 
2003 county business patterns (U.S. Census Bureau), Economic Research Service,  
1 “The biosciences are not just biotechnology but rather a range of industry sectors relying on 
insights into the way living organisms function.”( Battelle and SSTI, 2004). 
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National Agricultural Statistics Service, Battelle Technology Partnership Practice and 
SSTI (state-level data), and U.S. Dept. of Labor. The dependent variables considered in 
the study are: county level number of biotech establishments in 2003 (firms belonging to 
the aforementioned NAICS codes) and the change in county level biotech establishments’ 
from1998 to 2003. The study also analyzed the regional differences in factors affecting 
the location of new biotech establishments by employing a separate model for each of the 
four regions (South, Northeast, Midwest and West). 
 
Source: Battelle Technology Partnership Practice and State Science and Technology Institute. 2004. 
Figure 3.2. U.S. Employment Distribution Across the Bioscience Subsectors. 
 
 Economies of scale associated with agglomeration factors are believed to be one 
of the driving forces in the geographical distribution of the biotech industry (Pisano, 
Shan, and Teece, 1988; Gray and Parker, 1998; Goetz and Rupasingha, 2002; Munroe, 
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Craft, and Hutton, 2002; McCandless, 2005). Agglomeration economies indicate that 
performance of one biotech firm is influenced by the other biotech firms located nearby. 
The resulting spillovers may be due to an already existing industry-specific infrastructure, 
which is associated with lower transaction costs, proximity to research institutions and 
specialized intermediate industries, good transportation facilities, and availability of 
skilled labor pool and financial resources. The research oriented biotech firms generate 
externalities and spillovers, which tend to be spatially proximate to where they were 
created, resulting in positive economies of scale for firms located in that region (Jaffe, 
Trajtenberg, and Henderson, 1993; Dahlander and McKelvey, 2003). Zeller (2001) 
analyzed the spatial clustering of biotech firms in Germany and argued that, even though 
knowledge and technology transfer often happens on a global scale, the exchange of tacit 
knowledge, however, is facilitated by spatial proximity.  This approach of industrial 
cluster analysis is used by many economic development agencies to enhance regional 
growth. Akundi (2003) conducted a survey of state cluster initiatives and found that as 
many as 40 states in the U.S. consider industrial cluster analysis as their critical strategy 
to promote economic development.  In this study, we include a spatial lag variable as a 
proxy for agglomeration economies that accounts for the biotech establishment counts in 
neighboring counties. The variable is hypothesized to have a positive effect on the 
location of biotech firms. 
 A factor that is considered to be a prerequisite for attracting a biotech firm is 
proximity to research institutions. Several studies have analyzed the role of research 
institutes in the development and commercialization of biotechnology (Powell and 
Brantley, 1992; Darby and Zucker, 1996; Zucker, Darby, and Brewer, 1998; Prevezer, 
1998; Zucker, Darby, and Armstrong, 2003; Dahlander and McKelvey, 2003; Xia and 
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Buccola, 2005). Industry funded university research increased from $630 million in 1985 
to $2.1 billion in 2004 (National Science Foundation, 2006), indicating an increasing 
affiliation between university and industry in technology advancement. Some of the 
primary reasons for this collaboration include access to complementary research activity 
and human capital, increasing commercial opportunities, stringency of patent law and 
federal policies, and the relative decline of public research funding (Santoro and Alok, 
1999; Yang and Buccola, 2003).  This study includes county-level number of colleges, 
universities, and professional schools (colleges) as a proxy for the proximity to research 
institutions and assumes it will have a positive effect on the location of biotech industry. 
County-level data for this variable was collected from county business patterns (U.S. 
Census Bureau, 1998 and 2003) with 611310 NAICS classification, which includes 
number of colleges, universities, and professional schools.  
 Ongoing research intensity in life sciences at research institutions of a particular 
state is also considered to be a critical factor in the location decision of a biotech firm 
(Zucker, Darby, and Brewer, 1998; Munroe, Craft, and Hutton, 2002; Xia and Buccola, 
2005).  State level university life science Research &Development expenditures (R&D), 
National Institute of Health support for institutions (NIH), higher education degrees in 
biological science (Biological Degrees), and average biological scientists in the 
workforce 2000-2002 (Biological Scientists), are included as proxies for ongoing 
research intensity. All these variables are assumed to have a positive effect impact on the 
site-selection of a biotech firm. State level data for R&D expenditures was collected from 
National Science Foundation, whereas state level data for other three variables was 
collected from Battelle and SSTI (2004).  
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 Businesses that provide venture capital are considered to be an important source 
of capital, especially, for new and small firms (Powell, Koput, Bowie, and Smith-Doerr, 
2002).  For a small biotech firm, availability of venture capital in a particular region is as 
important as the strong research capacity of that region. During 2004, venture capital 
accounted for approximately 23.5% of the total financing for the biotech industry as 
indicated in figure 3.3 (BIO, 2005; BioWorld, 2005). Most of the biotech firms are small 
and operate at a loss, spending large amount of money on research and development for 
several years, before earning a profit (Cortright and Mayer, 2002). For example, only 1 in 
5,000 potential new medicines reach the pharmacy shelf, and that is after 12 to 15 years 
of R&D with an average expenditure of $500 million (California Trade and Commerce 
Agency, 2001). As a result, most of the small biotech firms depend on venture capital 
funds, on research contracts and equity investment from large biotech firms, and on sales 
of their company stock in public markets (Cortright and Mayer, 2002). Therefore, the 
availability of local venture capital firms (Venture Capital) is hypothesized to have a 
positive effect on the location of a biotech firm in that region (data for county-level 
number of venture capital establishments was collected from county business patterns 
with 523910 NAICS classification).   
 Agriculture is an important component of the biotech industry. Some studies have 
analyzed issues related exclusively to the spatial distribution of agricultural biotech firms 
and its relationship with research institutions (Kalaitzandonakes and Bjornson, 1997; 
Graff, 1997; Begemann 1997; Brennan, Pray, and Courtmanche, 1999; Sporleder, Moss, 
and Nickles, 2002; Yang and Buccola, 2003; Sporleder and Moss, 2004; Xia and 
Buccola, 2005). Around 13 percent of firms in biotechnology are primarily involved in  
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Figure 3.3. Biotech Industry Financing, 2004. 
 
 
agriculture (Dibner 1995; Graff 1997). As illustrated in figure 2, agriculture related 
biotech activities account for 17% of total U.S. employment across bioscience subsectors. 
According to Ernst and Young (2000), in 1999, agricultural biotech firms employed 
21,900 workers, generated $2.3 billion in revenues and $1.4 billion in personal income 
for employees and owners. The primary goal of agricultural biotechnology is to develop 
high yielding varieties with improved resistance to natural enemies (e.g. pest, diseases, 
weeds, and adverse growing conditions), and better quality and longer shelf life for fruits 
and vegetables (Ernst and Young, 2005). Since some of the biotech firms seek 
applications directed toward agricultural production, it is hypothesized that, in order to 
gain positive external economies of scale (low transaction costs), biotech firms prefer to 
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locate in regions with significant agricultural production (Farmland) (county level data 
for farmland was collected from U.S. Census of Agriculture). Similarly, since the biotech 
industry involves drugs and pharmaceutical firms, and medicinal devices and equipment 
firms, we hypothesize that a county with more hospitals (Hospitals) will have a positive 
effect on the location of the biotech industry. County-level data for this variable was 
collected from county business patterns (U.S. Census Bureau, 1998 and 2003) with 
622110 NAICS classification, which includes number of general medical and surgical 
hospitals.  
 In terms of conventional location theory, local property taxes (Property Tax) may 
discourage new investment by increasing the costs of production. However, in case of 
high-tech firms (such as the biotech industry), high property taxes are considered to be 
proxies for greater availability or higher quality of local public goods (Goetz and 
Rupasingha), which in turn reflects high standards of living of the local community. 
Therefore, we assume that property taxes are positively correlated with the location of 
biotech firms (county-level data for property tax collections was obtained from the U.S. 
Census Bureau). Similarly, counties with high unemployment (unemployment) and 
poverty rates (poverty), which reflect low standards of living of the local community, are 
considered to have a negative effect on the location-decision of biotech firms (county-
level data for unemployment and poverty rate are collected from Economic Research 
Service USDA and U.S. Bureau of Census, respectively). Similarly, counties with higher 
crime rates (Crime Index) are also considered to have a negative impact on the location of 
biotech firms.  County-level data for crime index was obtained from Geospatial and 
Statistical Data Center, University of Virginia Library. Urban economies are measured 
using the rural-urban continuum codes for U.S. counties, which range from 1 to 9, where 
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1 represents extremely urban and 9 represents extremely rural. They were further 
aggregated into two groups:  Metro (counties belonging to rural-urban continuum codes 
of 1-3) and Non-metro (counties belonging to rural-urban continuum codes of 4-9). The 
study assigns a value of 1 for non-metro counties and 0 for metro counties. Since, most of 
the existing biotech firms are located in the metropolitan cities; we hypothesize that the 
variable (Metro-Nonmetro) will have a negative impact on the location-decision of 
biotech establishments.  
 The impact of labor quality on the location decision of biotech industries is 
measured by county-level average wage per job (Wage) and percentage of persons with a 
college degree (Education) (Zucker, Darby, and Brewer, 1998). Both variables are 
considered to have a positive relationship with the site-selection of the biotech industry. 
County-level data for wage and education are obtained from the Bureau of Economic 
Analysis and Economic Research Service USDA, respectively. Biotech firms prefer to 
locate in highly populated centers (Population) as it provides appropriate services such as 
contracting for site building, major equipment, and availability of housing (McCandless, 
2005). Counties with high median household income (Income), which represents a high 
standard of living, are considered to have a favorable impact on the biotech firms’ site-
selection.  County-level data for population and median household income was obtained 
from U.S. Census Bureau and Economic Research Service USDA, respectively. 
Similarly, median housing values (Housing Value) are used as a proxy for the quality of 
housing in a given county. It is expected to have a positive impact on the location-
decision. County-level data for median housing value was obtained from U.S. Census 
Bureau. Table 3.1 and 3.2 presents the descriptive statistics of all the variables included  
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Table 3.1. Summary Statistics of Variables Employed in the Spatial Tobit Model for 
U.S. Biotech Industry Location.  
   
Variable Mean Std. Dev. 
Total Number of Biotech Establishments (number)1 11.50 41.64 
Poverty Rate (percent) 13.36 4.89 
Population (number in 1000s) 92.92 303.47 
Owner-Occupied Housing Units: Median Value (in $1000) 80.93 41.94 
Unemployment Rate (percent) 5.97 1.96 
Median Household Income (in $1000) 36.73 9.28 
Total Number of Venture Capital Firms (number) 1.89 11.45 
Number of Colleges, Universities and Professional Schools (number) 1.08 4.86 
Number of General Medical and Surgical Hospitals (number) 1.75 3.70 
Average Wage per Job (in $1000) 27.05 5.79 
Percent of Persons with a College Degree (percent) 16.51 7.80 
Property Tax (in $1000) 22.74 23.41 
Crime Index (index in 100s) 35.95 139.73 
Land in Farm Acres (in 1000 acres) 301.14 385.21 
Metro-Nonmetro (dummy) 0.65 0.48 
University Life Science R&D Expenditures (in $1000) 563.61 573.18 
NIH Support for Institutions (in $1000) 427.71 516.33 
Higher Education Degrees in Biological Science (number in 100s) 27.26 21.44 
Biological Scientists in Workforce 2000-2002 Avg (number in 100s) 118.38 106.01 
Note: 1 text in parenthesis indicates units of measurement. 
 
Table 3.2. Summary Statistics of Variables Employed in the Spatial Tobit Model for 
Change in U.S. Biotech Industry Location.  
Variable Mean Std. Dev. 
Change in Biotech Establishments (number)1 1.75 6.30 
Change in Poverty Rate (percent) -1.32 1.96 
Change in Population (number) 6581.22 277954.70 
Change (1990-2000)2 in Owner-Occupied Housing Units: Median 
Value (dollars)  27172.60 19233.77 
Change in Unemployment Rate (percent) 0.81 1.98 
Change in Median Household Income (dollars) 2786.50 2449.81 
Change in Number of Venture Capital Firms (number) -0.31 3.22 
Change in Number of Colleges, Univ. and Professional Schools 
(number) 0.13 1.10 
Change in Number of General Medical and Surgical Hospitals 
(number) -0.05 0.91 
Change in Average Wage per Job (dollars) 4101.71 1779.04 
Change (1990-2000) in Percent of Persons with a College Degree 
(percent)  3.03 2.21 
Change (1997-2002) in Property Tax (in $1000)  -43909.30 272672.30 
Change (1998-2002) in Crime Index (index) -71.99 2474.28 
Change(1997-2002) in Land in Farm (acres)  163.96 113160.50 
Metro-Nonmetro (dummy) 0.65 0.48 
Change(1997-2002) in University Life Science R&D Expenditures 
(in $1000)  304.93 315.40 
Note: 1 text in parenthesis indicates units of measurement. 
          2 change in variables are measured from 1998 to 2003, unless mentioned otherwise. 
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in the spatial tobit model for the location of U.S. biotech industry and for change in the 
location of U.S. biotech industry, respectively.  
3.4 Spatial Exploratory Analysis 
 The spatial distribution of biotech firms based on 2003 county business pattern 
data is presented in figure 3.4. The figure illustrates standard deviations of biotech 
establishments with the mean of biotech establishments equal to 11.49. A high 
concentration of firms is seen in the Northeast and West, as well as in major metropolitan 
cities, which involve 519 counties, accounting for 16.68 percent of the total observations.  
Most counties that are without or not adjacent to a major metropolitan city are also 
without a biotech firm. These regions compose the remaining 2,592 counties, accounting 
in terms of the number of biotech establishments, where each of the top thirty counties 
include at least one major city in 2003. Figure 3.6 indicates the mean change in the 
number of biotech establishments (1998-2003) equal to 1.15. Most of the new biotech 
firms established between 1998 and 2003 are located in counties associated with major  
metropolitan cities. This implies that, the U.S. biotech industry exhibits a spatial pattern 
and it is not independently distributed over space. 
The spatial association of biotech firms is tested using a global Moran’s I, which 
measures similarities and dissimilarities in biotech establishments across neighboring 
counties (Anselin, 1995). For the number of biotech establishments, y, Morans’I is: 
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where wij indicates elements of the spatial weight matrix W (Rook contiguity weight 
matrix) between two points (i & j), μ the mean of all y observations, and i, j=1,…,n. A 
positive and significant value for Moran’s I indicate positive spatial correlation, 
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for 83.32 percent of the total observations. Figure 3.5 presents the top thirty U.S. counties  
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Figure 3.5. U.S. Biotech Establishments by County, 2003. 
 
Note: TE represents total number of biotech establishments in each county 
Figure 3.4. Spatial Distribution of the U.S. Biotech Establishments, 2003. 
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showing that counties with a high or low number of establishments are similar to their 
neighboring counties. Conversely, a negative and significant value for Moran’s I 
indicates negative spatial correlation, showing that counties with a high or low number of 
establishments are unlike their neighboring counties (Pacheco and Tyrrell, 2002). We 
calculate Moran’s I for the 2003 number of biotech establishments across all contiguous 
U.S. counties, employing GeoDa, spatial data analysis software.  The Moran’s I statistic 
is equal to 0.3058, indicating a significant strong positive spatial relationship.  However, 
in the case of uneven spatial clustering, global spatial indicators such as Moran’s I are 
found to be less useful. This resulted in a new general class of local spatial indicators 
such as Local Indicators of Spatial Association (LISA, also known as Local Moran), 
which measures the contribution of individual counties to the global Moran’s I statistic 
(Anselin, 1995).  The LISA statistic is calculated for the ith county as: 
Figure 3.6. Spatial Distribution of Change in the Number of U.S. Biotech 
Establishments from 1998-2003. 
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(3.2)    ∑=
j
jijii zwzI  
where wij indicates elements of the spatial weight matrix W (Rook contiguity weight 
matrix) between two points (i & j),  and zi and zj indicates the standardized number of 
establishments for county i and j, respectively.  The sum of LISAs (∑
i
iI  ) for all 
observations is proportional to global Moran’s I, implying that LISA statistic can be 
interpreted as indicators of local spatial clusters and as diagnostics for local instability 
(spatial outliers) (Anselin, 1995).  
 Figure 3.7 illustrates the biotech industry clusters produced by LISA. It indicates 
the locations with a significant Local Moran statistic classified by type of spatial 
correlation: (a) high-high association (HH), a county with many biotech firms has 
neighboring counties with many biotech firms; (b) low-low association (LL), a county 
with few biotech firms has neighboring counties with few biotech firms; (c) low-high 
association (LH), a county with few biotech firms has neighboring counties with many 
biotech firms; and (d) high-low association (HL) , a county with many biotech firms has 
neighboring counties with few biotech firms. The HH and LL locations suggests  
clustering of similar values (positive spatial correlation), whereas the HL and LH 
locations indicate spatial outliers (negative spatial correlation) (Anselin, 1995). A 
positive and high autocorrelation is found in California, the Northeast, as well as in major 
cities such as Seattle, Portland, Salt Lake City, Phoenix, Denver, Houston, Dallas, 
Minneapolis, Chicago, Detroit, Cleveland, Cincinnati, Atlanta, Miami, Orlando, Tampa, 
and Raleigh. Figure 3.8 indicates locations with a significant Local Moran statistic. It 
illustrates that Imperial County (CA), Orange County (CA), Riverside County (CA), San 
Mateo County (CA), Lee County (KY), and Grant County (WV) have the most 
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significant biotech clusters among all U.S. counties, which is indicated by a p-value of 
0.0001. 
In addition to the spatial autocorrelation, multivariate spatial correlation is also 
analyzed employing a multivariate Moran’s I statistic. The multivariate spatial correlation 
“centers on the extent to which values of one variable (zk) observed at a given location 
show a systematic (more than likely under spatial randomness) association with another 
variable (zl) observed at the neighboring locations.” (Anselin, Syabri, and Smirnov, 
2002). The multivariate Moran’s I is as follows: 
(3.3)    
n
WzzI lkkl
'
=  
Where n indicates the number of observations, W indicates rook contiguity weight 
matrix, and zk and zl indicate standardized variables with mean zero and standard 
 
 
 
 
Figure 3.7. Local Indicator of Spatial Association (LISA) Cluster Map for Biotech 
Establishments.  
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deviation equal to one (Anselin, Syabri, and Smirnov, 2002). Using a similar rationale as 
in the development of LISA, a Multivariate Local Moran Statistic (MLMS) was 
developed by Anselin, Syabri, and Smirnov (2002). This is defined as follows: 
(3.4)    jl
j
ij
i
k
i
kl zwzI ∑=  
where wij indicates elements of the spatial weight matrix, W (Rook contiguity weight 
matrix) between points (i & j), and ikz  and 
j
lz  indicates the standardized variables for 
county i and j, respectively.  The MLMS “gives an indication of the degree of linear 
association (positive or negative) between the value for one variable at a given location i 
and the average of another variable at neighboring locations.” (Anselin, Syabri, and 
Smirnov, 2002). Similar to LISA, MLMS suggests two classes of positive spatial 
correlation, or spatial clusters (HH and LL), and two classes of negative spatial 
correlation, or spatial outliers (HL and LH) (Anselin, Syabri, and Smirnov, 2002). 
Figure 3.8. Local Indicator of Spatial Association (LISA) Significance Map for 
Biotech Establishments.  
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 Since the affect of agricultural production on the location of the agricultural 
biotech industry is of potential interest to the agricultural economists, this study analyzes 
spatial correlation between Farmland and spatial lag of the number of agricultural 
biotech establishments (agricultural feedstock subsector). The Multivariate Global 
Moran’s I statistic is equal to 0.0218, indicating a significant positive spatial relationship 
between agricultural production and the location of the agricultural biotech industry. The 
MLMSs cluster map indicates a positive spatial correlation in California, and parts of 
Midwest, West, Texas and Florida, whereas a negative spatial correlation is seen mainly 
in the Northeast and Central U.S.,  and parts of Midwest, West and Florida (figure 3.9). 
The significance of the MLMSs spatial clusters is illustrated in figure 3.10. This indicates  
 
 
 
 
 
 
Figure 3.9. Bivariate LISA Cluster Map for Farmland and Spatial Lag of Biotech 
Establishments.  
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that globally, agricultural production and the agricultural biotech industry have a positive 
relation; moreover, locally there are certain counties where spatial association is very  
significant.   
 
 
 
3.5 Econometric Model  
Most of the previous empirical studies on industry location have employed non-spatial 
econometric models, such as Ordinary Least Squares (OLS), Poisson, Negative Binomial, 
and Tobit  (for recent exception see Roe, Irwin, and Sharp,2002; Goetz and Rupasingha, 
2002; Isik, 2004; and Sambidi and Harrison, 2005). Since the data are collected with 
reference to points in space, employing OLS (and models mentioned above) as an 
econometric tool will produce spatially autocorrelated residuals, resulting in biased 
estimates and all inferences based on the model may be incorrect (Anselin, 1988; LeSage, 
1999).  
Figure 3.10. Bivariate LISA Significance Map for Farmland and Spatial Lag of 
Biotech Establishments.  
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 The spatial correlation of OLS residuals (without spatial component) is formally 
tested employing different spatial correlation indices (Morans-I, Wald, Lagrange 
multiplier and the Likelihood ratio test statistic), as suggested by LeSage (1999). All the 
tests indicated the presence of spatially correlated residuals in the regression model 
(Table 3.3). To overcome this problem of spatial autocorrelation, different approaches 
were undertaken, which involved spatial weights matrices (for example, spatial 
autoregressive model (SAR) and Spatial Error Model (SEM)). However, spatial 
correlation of data involving discrete dependent variables, have received little attention in 
the literature. In contrast to general spatial models, estimation of spatial discrete models 
yields a non-spherical variance covariance matrix, resulting in a heteroskedastic error 
term (Anselin 2002; Fiva and Rattsø, 2005).  To solve this problem, McMillen (1992) 
employed an error model (EM) algorithm approach to estimate the SAR and SEM probit 
models containing spatial heteroskedasticity. However, McMillen’s EM estimator is 
associated with certain drawbacks (LeSage, 2000), which were overcome by LeSage 
(2000), who developed a Gibbs sampling approach to estimate heteroskedastic spatial 
autoregressive and spatial error probit and tobit models.  
Table 3.3. Tests for Spatial Correlation in Residuals of a Regression Model.  
 
Test Statistics  Value 
Moran’s I Statistic 9.112*** 
Lagrange Multiplier  77.370***
Likelihood Ratio  69.765***
Wald  826.400***
Note: *** indicates significance at the 1% level 
 
The dependent variable (number of biotech establishments) contains 561 
observations with zeros, and a data range of 0 to 951. In this study the number of biotech 
establishments in a given county is assumed to reflect the strength of that county in 
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attracting new biotech establishments. Counties without biotech establishments are 
considered to be undesirable for biotech firm location, but we are not certain how much 
undesirable those counties are. This introduces a censor data problem into the estimation 
and thus more traditional methods (such as count data models) cannot be used for the 
estimation (Long 1997). Therefore, the study uses spatial tobit model over spatial count 
data models for the estimation. The dependent variable accounting for the change in the 
number of biotech establishments ranged from -66 to +207. During 1998 to 2003, while 
some (887) counties lost biotech establishments, some (900) had zero biotech 
establishments in 1998 and 2003 or the numbers did not change over the period. Goetz 
and Rupasingha (2002) indicated that the local factors explaining the growth of an 
industry are different from those explaining decline. Therefore, negative values of this 
dependent variable are recoded to zero because we are focusing on determining the 
factors affecting the location of new biotech establishments. Theoretically the tobit 
method is considered to be the most suitable approach when the underlying dependent 
variable contains negative values that have been censored (clustered) to zero in the 
empirical apprehension of the variable (Sigelman and Zeng 1999).  The spatial tobit 
model with a spatial lag variable is as follows:  
 
(3.5) 
),0(~ 2 nIN
yy
σμ
μβρ ++= XW
 
 
where y is a n x 1 vector of  the dependent variable (either the number of establishments 
in 2003 or change in the number of establishments  between 1998 and 2003), ρ is the 
scalar for spatial lag coefficient, W is the n x n spatial weigh matrix, β is the k x 1 
parameter vector, X is the n x k matrix of exogenous explanatory variables, μ is an n x 1 
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vector of normally distributed error terms with zero mean and variance σ2. The model is 
estimated employing a Bayesian estimation method provided by LeSage’s econometric 
toolbox (2005). The Bayesian approach is a Gibbs sampling (Markov Chain Monte Carlo 
(MCMC)) method, which allows prior knowledge to be introduced when available, or 
implements diffuse priors in model estimation (LeSage 2000). The study refers to LeSage 
(2000) and Casella and George (1992) for detailed presentation of Bayesian Spatial Tobit 
model and Gibbs sampling MCMC method, respectively. The Gibbs sampling approach 
introduces a conditional distribution for the censored dependent variable conditional on 
all other parameters in the model (Fiva and Rattsø 2005). Once the unobserved latent 
variables are generated they are used in place of the censored observations of the 
dependent variable in the tobit model (LeSage 2000). The Bayesian approach of the 
spatial tobit model relaxes the assumption of constant variance of error terms made by the 
maximum likelihood estimation even after controlling for spatial dependence (LeSage 
2000; Fleming 2004). 
3.6 Results 
Table 3.4 presents the parameters estimates and marginal effects of the spatial and 
standard tobit models of the biotech establishments along with the marginal effects. 
Tables 3.5-3.9 presents the parameter estimates and marginal effects of the spatial and 
standard tobit model of the change in the number of biotech establishments for the U.S., 
South, Northeast, Midwest, and the West, respectively. Relatively small standard errors 
for the spatial tobit model, compared to the standard tobit, indicated that the former is a 
better fit. Moreover, the highly significant spatial lag parameter (ρ) (except the Northeast 
equation) suggests that inference based on the standard tobit specification without a 
spatial correction, is not valid for the data under consideration.   
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 Table 3.4. Estimates of Factors Affecting the Location of U.S. Biotech Industry.  
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit  Spatial Tobit  Tobit 
Constant -2.6763***
(0.9169) 
-42.2665*** 
(5.3442) 
-0.4902 -27.0928 
Poverty 0.0099 
(0.0241) 
0.3575* 
(0.1655) 
0.0018 0.2291 
Population 2.90E-05*** 
(9.31E-06) 
0.0970*** 
(0.0056) 
5.31E-06 0.0622 
Median Housing Value -1.68E-05*** 
(3.67E-06) 
-0.0033 
(0.0197) 
-3.08E-06 -0.0021 
Unemployment -0.0536* 
(0.0366) 
-0.2853 
(0.2878) 
-0.0098 -0.1829 
Median Household Income 0.0001*** 
(2.22E-05) 
0.2934** 
(0.1189) 
1.63E-05 0.1881 
Venture Capital 0.4466*** 
(0.0849) 
0.4667*** 
(0.0572) 
0.0818 0.2991 
Colleges 0.5343*** 
(0.1074) 
1.5797*** 
(0.2166) 
0.0979 1.0126 
Hospitals 0.4801*** 
(0.0876) 
0.2760 
(0.3258) 
0.0879 0.1769 
Average Wage Per job 1.41E-05 
(1.46E-05) 
0.5906*** 
(0.1113) 
2.57E-06 0.3786 
Education 0.0504*** 
(0.0144) 
0.4267*** 
(0.0880) 
0.0092 0.2735 
Property Tax 2.33E-05*** 
(7.39E-06) 
0.0078 
(0.0221) 
4.26E-06 0.0050 
Crime Index 0.0001 
(0.0001) 
0.0032*** 
(0.0011) 
1.23E-05 0.0020 
Farm Land 1.66E-07 
(1.64E-07) 
-0.0006*** 
(0.0001) 
3.05E-08 -0.0004 
Metro-NonMetro 0.2688* 
(0.1767) 
2.1332* 
(1.0991) 
0.0492 1.3674 
Life Science R&D  -0.0010 
(0.0008) 
-0.0192*** 
(0.0047) 
-0.0002 -0.0123 
NIH 0.0009**
(0.0005) 
0.0157*** 
(0.0027) 
0.0002 0.0101 
Degrees in Biological 
Science 
0.0043 
(0.0126) 
0.0355 
(0.0870) 
0.0008 0.0228 
Biological Scientists in 
workforce 
-0.0005 
(0.0031) 
0.0381* 
(0.0200) 
-0.0001 0.0244 
rho 0.0242*** 
(0.0078) 
 
  
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors.
 
The spatial lag coefficient (ρ) is positive and significant at the 1% level, except for the 
change in biotech establishments’ equation of the West, where it was found to be 
significant at the 10% level. This result indicates the presence of spatial agglomeration 
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economies for the spatial structure of the biotech industry. The positive sign indicates that 
the spatial distribution of biotech firms is positively correlated across counties. The 
spatial agglomeration parameter being positive and significant in the change in biotech 
establishments’ equation indicates the willingness of new biotech firms to locate in 
regions with existing biotech companies. As mentioned earlier, agglomeration factors 
result in economies of scale, which create a favorable infrastructure for new and existing 
biotech firms. Hence, counties producing biotech products tend to be concentrated across 
regions in order to utilize positive externalities associated with agglomeration economies.  
 Most of the county-level variables in the spatial tobit model of the biotech 
establishments have the expected signs and are significantly different from zero. A 
county’s population had an expected positive sign, and was found to be significant at the 
1% level. This is in accordance with the present spatial distribution of biotech firms, 
which are located mainly in major metropolitan cities that are highly populated. 
However, change in population was found to be insignificant in the spatial tobit models 
of the change in biotech establishments, except the South where it was found to be 
positive and significant at the 5% level. 
 The median housing value had a negative and significant impact on the location 
of biotech firms, indicating that biotech firms avoid locating in a county with high 
housing values. Among the models accounting for the change in biotech establishments, 
the change in median housing value variable was found to be negative and significant (at 
the 10% level) in the Northeast and West. This result is some what surprising since most 
of the biotech firms are located in the urban areas of the Northeast and West, where 
housing costs are considered to be high. However, increasing housing values might be 
considered as one of the primary reasons for the emergence of new biotech regions such 
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as, Dallas, Houston, San Antonio, Memphis, Richmond, and Miami-Dade (McCandless 
2005). Moreover, Goetz and Rupasingha (2002) also found that the median housing 
values have a negative and significant impact on the growth of U.S. high-tech firms, 
which prefer to locate in metropolitan areas. 
Table 3.5. Estimates of Factors Affecting the Change in New U.S. Biotech 
Establishments.  
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit Spatial Tobit Tobit 
Constant -0.4813*** 
(0.1957) 
-7.6844*** 
(0.8019) -0.2612 -2.6687 
Poverty 0.0969*** 
(0.0301) 
0.4296*** 
(0.1305) 0.0526 0.1492 
Population 1.26E-07 
(2.41E-07) 
2.17E-06*** 
(8.19E-07) 6.82E-08 7.54E-07 
Median Housing Value -1.88E-06 
(3.14E-06) 
5.00E-06 
(1.20E-05) -1.02E-06 1.74E-06 
Unemployment 0.0248 
(0.0268) 
0.1080 
(0.1160) 0.0135 0.0375 
Median Household Income -1.15E-05 
(2.31E-05) 
0.0001 
(0.0001) -6.24E-06 0.0000 
Venture Capital 0.0359 
(0.0328) 
0.4638*** 
(0.0662) 0.0195 0.1611 
Colleges 0.2169*** 
(0.0921) 
1.6237*** 
(0.1847) 0.1177 0.5639 
Hospitals 0.0608 
(0.0765) 
0.1853 
(0.2090) 0.033 0.0644 
Average Wage Per job 0.0001*** 
(3.11E-05) 
0.0006*** 
(0.0001) 4.01E-05 0.0002 
Education 0.1199*** 
(0.0274) 
0.3665*** 
(0.1078) 0.0651 0.1273 
Property Tax -8.13E-07** 
(5.00E-07) 
-7.73E-06*** 
(9.04E-07) -4.41E-07 -2.68E-06 
Crime Index 1.73E-05 
(3.78E-05) 
0.0003*** 
(0.0001) 9.41E-06 0.0001 
Farm Land 6.68E-08 
(4.88E-07) 
-9.71E-07 
(1.81E-06) 3.63E-08 -3.37E-07 
Metro-Nonmetro -0.3989*** 
(0.1189) 
-1.6831*** 
(0.4825) -0.2165 -0.5845 
Life Science R&D   0.0002 
(0.0002) 
0.0039*** 
(0.0006) 8.31E-05 0.0014 
rho 0.2141*** 
(0.0287)    
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors. 
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The unemployment rate had an expected negative sign and was found to be significant (at 
the 10% level) in the spatial tobit model of the biotech establishments. This result is in 
accordance with the fact that high unemployment rate reflects a lower local quality of life 
or a weak economy, which is not generally preferred by biotech firms (Goetz and  
Table 3.6. Estimates of Factors Affecting the Change in New Biotech Establishments 
in the South.  
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit Spatial Tobit Tobit 
Constant -0.3353* 
(0.2544) 
-6.0870*** 
(0.9855) -0.1933 -0.0006 
Poverty 0.0782** 
(0.0400) 
0.3817** 
(0.1530) 0.0451 3.82E-05 
Population 9.20E-07** 
(3.99E-07) 
6.00E-06*** 
(1.56E-06) 5.30E-07 6.00E-10 
Median Housing Value -1.97E-06 
(7.61E-06) 
3.05E-06 
(2.86E-05) -1.14E-06 3.05E-10 
Unemployment -0.0493** 
(0.0306) 
-0.1098 
(0.1251) -0.0284 -1.10E-05 
Median Household Income -1.50E-06 
(3.41E-05) 
0.0001 
(0.0001) -8.67E-07 8.18E-09 
Venture Capital -0.0149 
(0.0409) 
0.1454 
(0.0952) -0.0086 1.45E-05 
Colleges 0.1141 
(0.1122) 
1.2735*** 
(0.2954) 0.0657 0.0001 
Hospitals 0.0774 
(0.1034) 
0.3476 
(0.3033) 0.0446 3.48E-05 
Average Wage Per job 3.73E-05 
(3.52E-05) 
0.0004*** 
(0.0001) 2.15E-05 4.11E-08 
Education 0.1051*** 
(0.0389) 
0.4605*** 
(0.1447) 0.0606 4.60E-05 
Property Tax -2.97E-07 
(8.41E-07) 
-4.99E-06** 
(2.36E-06) -1.71E-07 -4.99E-10 
Crime Index -0.0001* 
(0.0001) 
3.08E-05 
(1.19E-04) -4.78E-05 3.08E-09 
Farm Land 1.05E-06 
(9.80E-07) 
2.84E-06 
(4.27E-06) 6.05E-07 2.84E-10 
Metro-Nonmetro -0.5040*** 
(0.1508) 
-1.4942*** 
(0.3985) -0.2905 -0.0001 
Life Science R&D   0.0002 
(0.0002) 
0.0016* 
(0.0009) 0.0001 1.56E-07 
rho 0.2110*** 
(0.0399)    
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors. 
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Rupasingha, 2002). The results indicate that, as the unemployment rate in a particular 
county increases by 1%, possibility of locating a biotech firm in that county decreases by 
0.0098 units. Conversely, the variable was found to be insignificant in the standard tobit 
model, which failed to account for spatial autocorrelation. Among the change in biotech  
Table 3.7. Estimates of Factors Affecting the Change in Biotech Establishments in 
the West.  
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit Spatial Tobit Tobit 
Constant -0.4925 
(0.6648) 
-4.6392 
(3.4836) -0.2639 -1.5575 
Poverty 0.0063 
(0.0892) 
0.2808 
(0.5223) 0.0034 0.0943 
Population 8.75E-07 
(1.44E-06) 
1.66E-05** 
(6.85E-06) 4.69E-07 5.58E-06 
Median Housing Value -1.29E-05* 
(8.24E-06) 
-1.03E-04** 
(4.70E-05) -6.94E-06 -3.47E-05 
Unemployment 0.2398***
(0.0903) 
1.2523** 
(0.5172) 0.1285 0.4204 
Median Household Income 0.0001 
(0.0001) 
0.0007 
(0.0004) 4.61E-05 0.0002 
Venture Capital 0.0661 
(0.1084) 
1.2022*** 
(0.2153) 0.0354 0.4036 
Colleges 0.7215***
(0.3027) 
0.4966 
(0.5778) 0.3866 0.1667 
Hospitals 0.0837 
(0.2925) 
-0.2694 
(0.8160) 0.0449 -0.0905 
Average Wage Per job 0.0002** 
(0.0001) 
0.0003 
(0.0005) 0.0001 0.0001 
Education 0.0241 
(0.0768) 
0.0825 
(0.4556) 0.0129 0.0277 
Property Tax -5.77E-06*** 
(2.73E-06) 
-2.61E-05*** 
(4.02E-06) -3.09E-06 -8.75E-06 
Crime Index -0.0002* 
(0.0002) 
0.0006 
(0.0004) -1.24E-04 0.0002 
Farm Land -4.50E-07 
(7.76E-07) 
-4.92E-06 
(3.34E-06) -2.41E-07 -1.65E-06 
Metro-Nonmetro -1.0068** 
(0.4748) 
-4.7887* 
(2.4826) -0.5395 -1.6077 
Life Science R&D   0.0006* 
(0.0004) 
0.0043** 
(0.0019) 0.0003 0.0014 
rho 0.0900* 
(0.0545)    
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors. 
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establishment models, the change in unemployment variable was found to be negative 
and significant (at the 5% level) in the South, whereas it was found to be positive and 
significant (at the 1% level) in the West. The reason for this can be attributed to the fact 
that unemployment rate is high in the South compared to the West. High unemployment 
rate in the South indicates high poverty and low standards of living, which is not  
Table 3.8. Estimates of Factors Affecting the Change in Biotech Establishments  in 
the Midwest.  
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit Spatial Tobit Tobit 
Constant -0.5450 
(0.4836) 
-3.2227*** 
(0.8961) -0.2932 -1.3707 
Poverty 0.1185** 
(0.0630) 
0.1639 
(0.1242) 0.0638 0.0697 
Population 7.09E-08 
(3.73E-07) 
-5.41E-07 
(6.34E-07) 3.81E-08 -2.30E-07 
Median Housing Value 2.42E-06 
(9.02E-06) 
3.90E-05** 
(1.68E-05) 1.30E-06 1.66E-05 
Unemployment 0.0611 
(0.0697) 
0.1619 
(0.1375) 0.0329 0.0689 
Median Household Income -8.91E-05** 
(4.37E-05) 
-0.0003*** 
(0.0001) -4.79E-05 -0.0001 
Venture Capital 0.1439* 
(0.1015) 
0.3045** 
(0.1277) 0.0774 0.1295 
Colleges 0.0290 
(0.2104) 
0.9265*** 
(0.2749) 0.0156 0.3940 
Hospitals -0.0392 
(0.1222) 
0.2563* 
(0.1518) -0.0211 0.1090 
Average Wage Per job 0.0001* 
(0.0001) 
0.0003*** 
(0.0001) 4.62E-05 0.0001 
Education 0.1552*** 
(0.0460) 
0.3204*** 
(0.0852) 0.0835 0.1363 
Property Tax -8.97E-07 
(9.49E-07) 
-2.15E-06** 
(1.09E-06) -4.83E-07 -9.16E-07 
Crime Index 3.02E-05 
(5.95E-05) 
-1.19E-05 
(6.58E-05) 1.62E-05 -5.05E-06 
Farm Land -6.53E-07 
(1.65E-06) 
-2.39E-07 
(2.88E-06) -3.52E-07 0.00 
Metro-Nonmetro 0.0243 
(0.2167) 
-0.4070 
(0.3935) 0.0131 -0.1731 
Life Science R&D   -0.0008 
(0.0006) 
-0.0003 
(0.0012) -0.0004 -0.0001 
rho 0.3983*** 
(0.0585)    
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors. 
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preferred by biotech firms. Conversely, low unemployment rate in the West indicates 
lack of skilled labor.  Therefore, biotech firms locating in the West prefer to locate in 
counties with high unemployment rate. Thus, change in unemployment rate is considered 
to have a parabolic effect on the location of biotech industry.  
Table 3.9. Estimates of Factors Affecting the Change in Biotech Establishments I in 
the Northeast. 
 
Variable 
Coefficients Marginal Effects 
Spatial Tobit Tobit Spatial Tobit Tobit 
Constant -1.3988 
(1.6577) 
-2.0580 
(3.5053) -0.5508 -0.0002 
Poverty 1.0563*** 
(0.3624) 
2.0950*** 
(0.7616) 0.4160 0.0002 
Population 3.62E-07 
(8.12E-07) 
3.61E-06** 
(1.81E-06) 1.42E-07 3.61E-10 
Median Housing Value -2.39E-05* 
(1.56E-05) 
-2.92E-05 
(3.73E-05) -9.42E-06 -2.92E-09 
Unemployment 0.1131 
(0.2787) 
-0.0412 
(0.6718) 0.0445 -4.12E-06 
Median Household Income 0.0004* 
(0.0002) 
0.0009** 
(0.0004) 0.0001 8.91E-08 
Venture Capital 0.4703*** 
(0.1469) 
1.2762*** 
(0.2389) 0.1852 0.0001 
Colleges -0.4130 
(0.3787) 
1.0210 
(0.6454) -0.1627 0.0001 
Hospitals 0.4907* 
(0.3841) 
1.2000* 
(0.6919) 0.1932 0.0001 
Average Wage Per job -3.19E-05 
(0.0003) 
-0.0005 
(0.0006) -1.26E-05 -5.20E-08 
Education 0.2650 
(0.2489) 
0.3274 
(0.5413) 0.1044 3.27E-05 
Property Tax -3.45E-06*** 
(1.17E-06) 
-9.29E-06*** 
(2.03E-06) -1.36E-06 -9.29E-10 
Crime Index 0.0001 
(0.0002) 
0.0004 
(0.0003) 3.66E-05 3.50E-08 
Farm Land 8.86E-06 
(2.55E-05) 
2.54E-05 
(0.0001) 3.49E-06 2.54E-09 
Metro-Nonmetro 0.0754 
(0.7469) 
-1.8444** 
(0.9432) 0.0297 -0.0002 
Life Science R&D   0.0021** 
(0.0011) 
0.0027 
(0.0024) 0.0008 2.70E-07 
rho 0.0100 
(0.1073)    
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors. 
 
A county’s median household income, which reflects the local standard of living, was 
found to have a positive and significant impact on the location of biotech firms. This 
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result is consistent with previous literature, which indicates biotech firms’ preference for 
locating in regions with a high standard of living and well developed infrastructure. The 
change in median household income variable was found to have a positive and significant  
 (at the 10% level) impact on change in  biotech firms in the Northeast, conversely, it had 
an unexpected significant negative sign in the model for the Midwest. Availability of 
local venture capital was also found to be positive and significant, indicating biotech 
firms’ dependency on local financial sources. As the number of venture capital firms in a 
given county increases by one unit, the chances of locating a biotech firm in that county 
increases by 0.082 units. The change in number of local venture capital firms’ variable 
was found to be critical mainly in the Northeast and Midwest, where it was found to be 
positive and significant at the 1% and 10% level, respectively. 
 The number of colleges and hospitals in a given county were also found to have a 
positive and significant impact on the location of the biotech industry. As the number of 
colleges and hospitals in a particular county increase by one unit, the number of biotech 
firms in that county increases by 0.098 and 0.088 units, respectively. Also noteworthy is 
that coefficient of hospitals in spatial tobit model is high compared to the one in the 
standard tobit model, which indicated a downward bias of the estimate. In the model 
accounting for the change in biotech establishments in the U.S., the change in number of 
colleges’ variable was found to be positive and significant at the 1% level, whereas, the 
change in number of hospitals variable was found to be insignificant. The change in 
number of colleges variable was found to be positive and significant (at the 1% level) in 
the West (insignificant in the rest of the regions), whereas, the change in number of 
hospitals variable was found to be positive and significant in the Northeast (insignificant 
in the rest of the regions). This result is in accordance with the fact that biotech firms in 
66 
 
the Northeast are mainly involved in the manufacturing and marketing of new drugs; 
conversely, firms in the West are mainly engaged in R&D activities, which involve 
research institutes.   
 In the model for the biotech establishments, the education variable which reflects 
the labor quality in a given county was positive, as expected, and was found to be 
significant at the 1% level. This result indicates biotech companies’ preference for 
counties with a skilled labor pool. However, the average wage per job variable was found 
to be insignificant in the location of biotech industry. In the model for change in biotech 
establishment (U.S.), both change in education and average wage per job variables were 
found to be positive and significant at the 1% level. Among the regional models, the 
change in average wage per job variable was found to be positive and significant in the 
West and Midwest regions, conversely, the change in education variable was found to be 
positive and significant in South and Midwest.  
 The property tax variable, which was used as a proxy for high standard of living, 
was found to have an expected positive sign and was significant at the 1% level. 
Conversely, the change in property tax variable was found to have a negative and 
significant impact in the models for the change in biotech establishments in the U.S., 
Northeast, and West regions. This result indicates that increase in local property taxes 
especially, in the Northeast, might be one of the reasons for the emergence of new 
biotech regions other than the West and Northeast. The urbanization economy (Metro-
Nonmetro) variable had an unexpected positive sign in the biotech establishments’ model 
and was found to be significant at the 10% level. Conversely, Goetz and Rupasingha 
(2002) indicated that rural counties have a negative and significant impact on the location 
of high-tech firms, which includes drugs and pharmaceuticals and R&D services.  The 
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reason for this may be attributed to the fact that, biotech establishments in our model 
include firms that are related to agriculture (agricultural feedstock and chemicals), and 
are assumed to be located in close proximity to rural areas, where farm production is 
high. Therefore, the sign of urbanization economies variable may be changed by the 
inclusion of agricultural biotechnology firms. However, the urbanization economy 
variable (Metro-Nonmetro) was found to have a negative and significant impact in the 
change in biotech establishment models of the U.S., South, and West, indicating the new 
biotech firms’ preference to locate in metro counties rather than non-metro counties.  
 A county’s poverty rate was found to have a insignificant impact on the location 
of the biotech industry. Conversely, the change in poverty rate variable was found to be 
positive and significant in all the change in biotech establishment models, except the 
West. A county’s crime index was found to be insignificant in the site-selection of 
biotech firms, which is consistent with Goetz and Rupasingha’s (2002) findings. 
However, the variable was found to be negative and highly significant in the standard 
tobit model, indicating a upward bias of the estimate that failed to correct for spatial 
autocorrelation. Among the spatial tobit models of the change in biotech establishments’ 
the change in crime index variable was found to be negative and significant in the South 
and West. This indicates that the new biotech firms’ willing to locate in the South or 
West, prefer to locate in counties that have low crime rate.  
 The amount of farmland in a given county was found to be insignificant in the 
location of biotech industry. In addition, the change in farmland variable was also found 
to be insignificant in all the change in biotech establishments’ models. The state level 
variables (R&D, NIH, Biological Degree, and Biological Scientists) were found to be 
insignificant, except for NIH, which was found to be positive and significant at the 5% 
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level. The reason for the insignificance of the rest of the variables may be attributed to 
the fact that they are all measured at the state level and were not able to capture the 
county level effects. The change in R&D expenditures variable was found to be positive 
and significant in the change in biotech establishment models of the West and Northeast. 
This result is in accordance with the current spatial concentration of biotech firms in the 
West and Northeast, which are involve states spending large amount of money on 
research and development.  
3.7 Conclusions 
Over the past two decades the U.S. biotech industry has experienced significant growth, 
resulting in an increase in size and number of establishments. Currently, several state and 
local economic development agencies are designing and implementing strategies to 
attract new biotech firms, resulting in stiff competition among and within states. As a 
result of this increasing competition, the U.S. biotech industry is experiencing some 
changes in its geographical distribution. However, only some new state/regions are likely 
to attract biotech firms, as most biotech firms are tending to cluster along existing biotech 
regions. Several studies have analyzed the location aspects of the biotech industry, 
however, our understanding of the spatial influence on the regional distribution of biotech 
establishments, is anecdotal. This study employs a Bayesian spatial tobit model that 
analyzes factors affecting site-selection of the U.S. biotech industry taking the spatial 
affect into consideration. The study examines the impacts of agglomeration factors, 
infrastructure factors, and local economic and socioeconomic factors on the county-level 
biotech establishments. A total of twenty five biotech related industries were analyzed in 
the study.  
The hypothesis of spatial agglomeration economies is confirmed for the spatial 
structure of the biotech industry, indicating that biotech firms are positively correlated 
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across counties, resulting in clustering of biotech production. Availability of venture 
capital firms, research institutions, and hospitals were found to have the most significant 
impact on the location of biotech firms. This indicates that the biotech firms prefers to 
locate in regions where they have a source for financing their business , access to 
research institutes to collaborate with skilled labor and obtain new technology, and access 
to hospitals for research, testing and marketing of new biotech products.  
Biotech companies also prefer to locate in counties with a well developed 
infrastructure. This is indicated by the positive and significant estimates of median 
household income, education, population, and property tax, and a negative and significant 
estimate of the unemployment rate. In terms of the theory of industry location, firms 
should prefer counties with low wages, low property taxes and high unemployment rate; 
however, the preference of biotech firms seen here is different. In the case of biotech 
industry location, these three variables are assumed to proxy the standard of living of a 
given county, thus, indicating their preference to locate in counties with a high standard 
of living.  
The above findings may hinder rural areas hopes of attracting biotech firms; 
however, they are capable of attracting at least one category of the biotech industry 
(Agricultural Feedstock and Chemicals), which is involved in the agricultural and biotech 
activities. The rural areas may also want to target the biotech firms that are involved in 
the manufacturing of intermediate products and drugs that have achieved commercial 
scale. These types of biotech firms are found to operate in locations that are associated 
with low costs of production, availability of space for expansion, low median housing 
values and good incentives (Gray and Parker, 1998).Thus, the state and local economic 
development agencies should design strategies based on the type of biotech firm they 
want to attract.  
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The regional models in this study also shredded some light on the regional 
differences in factors affecting the location of new biotech establishments. Prospective 
biotech firms willing to locate in the West prefer to establish in metro-counties with easy 
access to research institutes and skilled labor pool, and that are associated with low 
median housing values, property taxes, and crime rate. Since the existing biotech firms in 
the Northeast are mainly associated with manufacturing and marketing of biotech 
products, biotech firms preferences are different in the Northeast compared to other 
regions. Biotech firms that are willing to locate in the Northeast prefer counties with easy 
access to funding sources (venture capital firms and state incentives), hospitals for 
research, testing and marketing of new biotech products, and the ones that are associated 
with low median housing value and property tax. 
Future research is directed toward a separate analysis of factors affecting the 
location of agricultural and non-agricultural biotech firms. Including county-level 
variables related to the state and local economic development incentives, R&D 
expenditures, and environmental constraints may further enlighten our understanding of 
the biotech industry location.  
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CHAPTER 4 
SPATIAL CLUSTERING OF INNOVATIVE ACTIVITIES: A CASE OF U.S. 
BIOTECH RELATED RESEARCH AND DEVELOPMENT ACTIVITIES 
 
4.1 Background 
Over the past few decades there has been considerable scientific interest in understanding 
the forces that contribute to the clustering of innovative activities and growth potential of 
firms and regions. Similar to other high-tech firms, Research and Development (R&D) 
firms involved in biotech activities are receiving a wide spread attention based on their 
potential for exceptional growth. Compared to other traditional industries, R&D firms are 
considered to agglomerate and form clusters in specific areas. Knowledge spillovers are 
considered to be one of the main reasons for this geographical concentration of R&D 
firms (Acs et al. 1992, 1994; Feldman 1994a, b; and Audretsch and Feldman 1996). The 
role of these spillovers, which generate increasing returns and eventually economic 
growth, is the central theme of the new theory of endogenous growth (Romer 1986, 1990; 
Grossman and Helpman 1991).  
 A recent stream of literature involving economic geographers and location 
theorists have focused on analyzing different forms of agglomeration economies to better 
understand the theory behind industry location. The concept of agglomeration economies 
indicate that the performance of one firm is influenced by other firms located nearby. If a 
firm benefits by locating near an existing firm, it indicates positive economies of scale. 
Conversely, if a firm is deterred by locating near an existing firm, it indicates negative 
economies of scale. Agglomeration economies are further divided into Localization 
economies and Urbanization economies. Localization economies involve technical 
externalities and knowledge spillovers (Marshall-Arrow-Romer (MAR) externalities) that 
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are specific to an industry whereby the productivity or growth of a firm in a given 
industry in a given region is assumed to increase the performance of others firms in that 
industry (van Oort, 2004). The externalities and spillovers include: the formation of a 
skilled labor pool and the production of new ideas (based on accumulation of human 
capital and face to face communication) and the availability of specialized input services 
(Marshall, 1920; Ottaviano and Thisse, forthcoming). This type of economies results in 
specialization of a region with respect to a specific industry (Paci and Usai, 1999). 
Urbanization economies reflect economic externalities that are transferred to firms of 
different industries as a result of savings from large scale operation of a city as a whole 
(Jacobs 1969; van Oort, 2004).  It indicates economies of scale associated with 
generalized location factors such as good infrastructure, favorable community attitude, 
tax credits and subsidies, and favorable socioeconomic factors. These factors are not 
specific to a particular industry, but, favor any kind of industry. This in turn results in 
sectoral diversity, and that is why we see a wide variety of industries in major 
metropolitan areas. This type of economy is considered to be more significant for high-
tech industries, which are involved in innovative activities and depend on knowledge 
spillovers from outside the core industry (Henderson et al., 1995; Paci and Usai 1999). 
Generally speaking, there are two sources of spillovers: one is private-sector 
spillovers, which include existing R&D facilities, while the other is public-sector 
spillovers, which include public research institutions, such as universities, medical 
centers, and government laboratories (Kyle 2004; Furman et al. 2004). Krugman (1991) 
argue that knowledge spillovers especially, tacit knowledge from public and private R&D 
facilities to third-party firms are restricted by the distance between them. In fact, despite 
the technology advancement, knowledge is still considered to be costly and difficult to 
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transfer (Jaffe et al., 1993; von Hippel, 1994). This indicates that proximity and location 
play a key role in the success of a R&D firm (Audretsch and Feldman 1996). However, 
Furman et al. (2006) argue that the effectiveness of spillovers is not only dependent on 
spatial proximity, but also on the types of investment made by the recipient firm (Cohen 
and Levinthal, 1998) and on the nature of contractual agreement between the knowledge 
source and recipient. For instance, Zucker, Darby and Armstrong (1998) in their study 
indicated that the success of biotech firms is not driven by simple geographic proximity 
to research institutes with “star scientists’, but rather by the contractual agreements 
between particular firms and “stars” (Furman et al. 2006). Moreover, Toole (2003) argue 
that tacit knowledge can only be restricted for a short period of time since valuable 
thoughts and methods spread quickly (Feldman 2003). In this paper we try to incorporate 
these spatial issues in econometric modeling and estimate the influence of localization 
and urbanization economies on the spatial distribution of biotech related R&D and testing 
facilities. 
 Our objectives in this paper are twofold. First, we examine the inter- and intra-
industry spatial association of the biotech related R&D and testing facilities across all 
contiguous U.S. counties.  Second, we employ spatial econometrics to analyze the extent 
to which numerous firm-specific, location-specific, and inter- and intra-industry spatial 
agglomeration factors affect the location, movement and concentration of biotech related  
R&D and testing facilities. This type of econometric modeling will explicitly consider the 
potential for spatial effects such as spatial autocorrelation and spatial heterogeneity that 
may invalidate the interpretation of standard econometric analyses based on contiguous 
cross-sectional data (Anselin et al. 2000).  In most of the previous literature directed 
toward location of high-tech industries, these effects are typically excluded or treated 
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inappropriately (for recent exceptions, see Paci and Usai 1999; Anselin et al. 2000; Goetz 
and Rupasingha 2002). 
4.2 Location Choices for R&D Firms 
Gray and Parker (1998) argue that there are two choices for emerging R&D firms 
to locate. One is to locate in new regions without industrial history and where they can 
develop their own production unit and maximize their profits by restricting the spread of 
their knowledge.  These firms can also collaborate with local research institutes; 
however, they may have to set some contractual agreements to prevent the spread of 
knowledge to other emerging R&D firms that may wish to grasp that knowledge and 
develop their own facility in that region. Research institutes play a critical role in the 
spatial distribution of R&D firms. They are considered to be the source of basic research 
and high skilled labor (Anselin et al. 2000) for the high-tech industries. Knowledge 
created from basic research at universities is considered to be a public good; therefore, 
the resulting positive externalities are not locally bounded, but can freely move across 
borders to private sector in the form of spillovers (Anselin et al. 1997).   
The second choice is to locate in regions with well established firms, which create 
an infrastructure suitable for the new firms. In the case when emerging R&D firms 
believe incoming spillovers from existing firms are significant, they may tend to engage 
in cooperative R&D agreements (Cassiman and Veugelers 2002). Feldman et al. (2004) 
indicate that co-location of R&D firms facilitates knowledge spillovers by providing 
opportunities for both planned and unanticipated interactions. This type of knowledge 
spillovers are considered to be less costly compared to the ones generated internally, or 
sourced externally through contractual agreement (Feldman et al. 2004). Aharonson et al. 
(2004) found that a biotech firm R&D investments is more productive when it is located 
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close to other biotech firms that are working on similar issues. The authors also found 
that the productivity of a biotech firm is enhanced by its own R&D alliance and also 
R&D alliances of other firms located within a cluster. However, if the existing firms 
avoid cooperation, this may hinder the productivity of new firms. Kyle (2004) argue that 
proximity to R&D facilities of competing biotech firms that are publishing many 
scientific papers has some negative impact on R&D activities of a new or existing biotech 
firm. The author indicates two reasons for this negative impact. First, the firm, which is 
lagging behind, may cut back on its patenting efforts and reallocate its drug discovery 
expenditures from patenting to other functions. The second reason could be that a 
competitor may lock the access to research institutes for other firms, by making 
contractual agreements with researchers of that institute (Kyle 2004 and Furman et al. 
2004).  
4.3 Data  
 The present study analyzed several categories of variables that are considered to 
affect the location of biotech related R&D and testing facilities, such as agglomeration 
factors, infrastructure factors, and local economic and socioeconomic factors. County-
level data was obtained from the 2003 county business patterns (U.S. Census Bureau), 
Economic Research Service, National Agricultural Statistics Service, and U.S. Dept. of 
Labor. The dependent variable considered in the study is county level number of R&D 
and testing facilities (NAICS codes:  541380, 541710) in 2003.  
 Economies of scale associated with agglomeration factors are believed to be one 
of the driving forces in the geographical distribution of innovative activities, such as 
R&D and testing facilities (Pisano, Shan, and Teece, 1988; Audretsch and Feldman 1996; 
Gray and Parker, 1998; Paci and Usai 1999; Goetz and Rupasingha, 2002; Furman et al.  
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2005). Agglomeration economies indicate that performance of one R&D firm is 
influenced by the other R&D firm located nearby. The resulting spillovers may be due to 
an already existing industry specific infrastructure, which is associated with lower 
transaction costs, proximity to research institutions and specialized intermediate 
industries, good transportation facilities, and availability of skilled labor pool and 
financial resources. As mentioned earlier, R&D firms generate externalities and 
spillovers, which tend to be spatially proximate to where they were created, resulting in  
positive economies of scale for firms located in that region (Jaffe, Trajtenberg, and 
Henderson, 1993; Dahlander and McKelvey, 2003). Zeller (2001) analyzed the spatial 
clustering of biotech firms in Germany and argued that while codified knowledge and 
technology transfer often transmitted at low cost on a global scale, the exchange of tacit 
knowledge is facilitated more effectively by spatial proximity. In this study, we include a 
spatial lag variable as a proxy for agglomeration economies that accounts for R&D and 
testing facilities in neighboring counties. The variable is hypothesized to have a positive 
effect on the location of R&D and testing facilities. 
 A factor that is considered to be a prerequisite for attracting a R&D firm is 
proximity to research universities, which are responsible for knowledge spillovers and the 
supply of skilled labor pool. Industry funded university research increased from $630 
million in 1985 to $2.1 billion in 2004 (National Science Foundation, 2006), indicating 
an increasing affiliation between university and industry in technology advancement. 
Several studies have analyzed the relationship between university research and high-tech 
innovations (Audretsch and Feldman 1996; Anselin et al. 1997; Zucker, Darby, and 
Brewer, 1998; Prevezer, 1998; Anselin et al. 2000; Zucker, Darby, and Armstrong, 2003; 
Dahlander and McKelvey, 2003; Kyle 2004; Furman et al. 2005; Xia and Buccola, 2005). 
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Zucker et al. (1998) have noted that growth in biotechnology firms is largely influenced 
by the presence of “star” scientists at universities. Furman et al. (2006) argue that the 
spillovers from research universities (public spillovers) may play a major role in driving 
private sector productivity, as compared to the spillovers from other R&D firms (private 
spillovers). Generally speaking, R&D firms prefer to locate in close proximity of research 
institutes, because universities do not generally seek to secure the full value of the 
knowledge they create, and are likely to promote the spread (public spillovers) of that 
knowledge (Kyle 2004). The reason is that researchers at universities are generally 
rewarded for publishing their work and for the influence that work has on future research 
in that area (Kyle 2004). However, Anselin et al. (2000) argue that public spillovers are 
specific to certain industries. According to the authors, public spillovers are not 
significant in the Drugs and Chemicals (SIC28) and in the Machinery (SIC35) sectors, 
where as, they are evident in the Electronics (SIC36) and the Instruments (SIC38) 
sectors. In order to analyze the influence of research universities on the location of R&D 
firms, this study includes county-level number of colleges, universities, and professional 
schools (colleges) as a proxy for the proximity to research universities. We assume that it 
will have a positive effect on the location of R&D and testing firms. County-level data 
for this variable was collected from county business patterns (U.S. Census Bureau 2003) 
with 611310 NAICS classification, which includes number of colleges, universities, and 
professional schools.  
 Biotech related R&D and testing firms are mainly involved in the development of 
a new product, once the new product is developed and tested, it is produced in relatively 
large batches at regional manufacturing firms (pilot plants). These manufacturing firms 
are generally located in close proximity of R&D and testing firms, because 
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manufacturing the new biotech products is increasingly complex and difficult, and 
require a set of highly skilled workforce (Pisano, 1997; Lee and Burrill, 1995; Gray and 
Parker, 1998).  Once the new biotech product gets FDA approval its production shifts 
from pilot plants to the commercial plants, where it is produced on a large scale. 
Commercial production of the new biotech product involves two stages: 1) production of 
high-value intermediate active ingredient, and 2) formulation and packaging of the final 
product (Gray and Parker 1998). Generally, the first stage is performed at manufacturing 
plants that are nearby R&D firms, whereas the second stage is performed at 
manufacturing plants located in low-cost regions (Gray and Parker 1998). In this study, 
we include county-level number of biotech related manufacturing firms (Manufacturing)1 
as one of the explanatory variables and hypothesize that it will have a positive effect on 
the location of  R&D and testing firms in that region.   
 Businesses that provide venture capital are considered to be an important source 
of capital, especially, for new and small firms (Powell, Koput, Bowie, and Smith-Doerr, 
2002).  For a small R&D firm, availability of venture capital in a particular region is as 
important as the strong research capacity of that region. During 2004, venture capital 
accounted for approximately 23.5% of the total finance for the biotech industry (BIO, 
2005; BioWorld, 2005). Most of the biotech related R&D firms are small and operate at a 
loss, spending large amount of money on research and development for several years, 
before earning a profit (Cortright and Mayer, 2002). For example, only 1 in 5,000 
potential new medicines reach the pharmacy shelf, and that is after 12 to 15 years of 
R&D with an average expenditure of $500 million (California Trade and Commerce  
 1the biotech related manufacturing firms belong to the following NAICS codes: 311221, 311222, 
311223, 325193, 325199, 325221, 325222, 325311, 325312, 325314, 325320, 424910, 325411, 
325412, 325413, 325414,339111, 339112, 339113, 339114, 334510, 334516, and 334517. 
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Agency, 2001). As a result, most of the biotech related R&D firms depend on venture 
capital funds, on research contracts and equity investment from large R&D firms, and on 
sales of their company stock in public markets (Cortright and Mayer, 2002). Therefore, 
the availability of local venture capital firms (Venture Capital) is hypothesized to have a 
positive effect on the location of R&D and testing firms in that region (data for county-
level number of venture capital establishments was collected from county business 
patterns with 523910 NAICS classification).   
.   Agriculture is an important component of the biotech industry. Some studies have 
analyzed issues related exclusively to the spatial distribution of agricultural biotech R&D 
firms and its relationship with research institutions (Kalaitzandonakes and Bjornson, 
1997; Graff, 1997; Begemann 1997; Brennan, Pray, and Courtmanche, 1999; Sporleder, 
Moss, and Nickles, 2002; Yang and Buccola, 2003; Sporleder and Moss, 2004; Xia and 
Buccola, 2005). The primary goal of agricultural biotech related R&D firms is to develop 
high yielding varieties with improved resistance to natural enemies (e.g. pest, diseases, 
weeds, and adverse growing conditions), and better quality and longer shelf life for fruits 
and vegetables. Since some of the biotech related R&D firms seek applications directed 
toward agricultural production, it is hypothesized that, in order to gain positive 
economies of scale (low transaction costs), R&D firms prefer to locate in regions with 
significant agricultural production (Farmland) (county level data for farmland was 
collected from U.S. Census of Agriculture). Similarly, since the biotech industry involves 
drugs and pharmaceutical firms, and medicinal devices and equipment firms, we 
hypothesize that a county with more hospitals (Hospitals) will have a positive effect on 
the location of R&D and testing firms (U.S. Census Bureau, 1998 and 2003) with 622110 
NAICS classification, which includes number of general medical and surgical hospitals.  
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. In terms of conventional location theory, local property taxes (Property Tax) may 
discourage new investment by increasing the costs of production. However, in case of 
high-tech firms (such as R&D firms), high property taxes are considered to be proxies for 
greater availability or higher quality of local public goods (Goetz and Rupasingha  2002), 
which in turn reflects a high standards of living of the local community. Therefore, we 
assume that property taxes are positively correlated with the location of R&D firms 
(county-level data for property tax collections was obtained from the U.S. Census 
Bureau). Similarly, counties with high unemployment rate (unemployment) and poverty 
rate (poverty), which reflect a low standard of living of the local community, are 
considered to have a negative effect on the location-decision of R&D firms(county-level 
data for unemployment and poverty rate are collected from Economic Research Service 
USDA and U.S. Bureau of Census, respectively). Similarly, counties with higher crime 
rates (Crime Index) are also considered to have a negative impact on the location of R&D 
firms.  As indicated earlier, the R&D industry is mainly concentrated in the metropolitan 
areas, which account for 92% of the total number of R&D and testing facilities in 2003. 
County-level data for crime index was obtained from Geospatial and Statistical Data 
Center, University of Virginia Library. In order to measure the impact of economies on 
the location of R&D firms, we group U.S. counties into Metro (counties belonging to 
rural-urban continuum codes of 1-3) and Non-metro (counties belonging to rural-urban 
continuum codes of 4-9). The study assigns a value of 1 for non-metro counties and 0 for 
metro counties. Since most of the existing R&D firms are located in the metropolitan 
cities, the study hypothesize that the variable (Metro-Nonmetro) will have a negative 
impact on the location-decision of the new R&D firms.  
86 
 
 The impact of labor quality on the location decision of R&D firms is measured by 
county-level average wage per job (Wage) and percentage of persons with a college 
degree (Education) (Zucker, Darby, and Brewer, 1998). Both variables are considered to 
have a positive relationship with the site-selection of the R&D industry. County-level 
data for wage and education are obtained from the Bureau of Economic Analysis and 
Economic Research Service USDA, respectively. R&D firms prefer to locate in highly 
populated centers (Population) as it provides appropriate services, such as contracting for 
site building, major equipment, and availability of housing (McCandless, 2005). Counties 
with median household incomes (Income), which represents a high standard of living, are 
considered to have a favorable impact on R&D firms’ site-selection (county-level data for 
population and median household income was obtained from U.S. Census Bureau and 
Economic Research Service USDA, respectively).  Similarly, median housing values 
(Housing Value) are used as a proxy for the quality of housing in a give county. County-
level data for median housing value was obtained from U.S. Census Bureau.It is expected 
to have a positive impact on the location-decision. County-level data for median housing 
value was obtained from U.S. Census Bureau. Table 4.1 presents the descriptive statistics 
of all the variables included in the model. 
4.4 Spatial Exploratory Analysis 
The spatial distribution of R&D firms based on 2003 county business pattern data is 
presented in figure 4.1. The figure illustrates standard deviations of R&D and testing 
establishments with the mean equal to 6.05. A high concentration of firms is seen in the 
Northeast and West, as well as in major metropolitan cities, which involve 408 counties, 
accounting for 13 percent of the total observations. Most counties that are without or not 
adjacent to a major metropolitan city, are also without R&D and testing firms. Figure 4.2 
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presents the top twenty U.S. counties in terms of the number of R&D and testing 
establishments, where each of the top twenty counties included at least one major city. 
This implies that, the U.S. R&D and testing industry exhibit’s a spatial pattern, and it is 
not independently distributed over space.  
Table 4.1. Summary Statistics of Variables.   
Variable Mean Std. Dev. 
Total Number of R&D and Testing  Establishments (number)1 6.06 28.41 
Nonmetro-Metro (dummy) 0.65 0.48 
Poverty Rate (percent) 13.36 4.89 
Population (number in 1000s) 92.92 303.47 
Owner-Occupied Housing Units: Median Value (in $1000) 80.93 41.94 
Unemployment Rate (percent) 5.97 1.96 
Median Household Income (in $1000) 36.73 9.28 
Total Number of Venture Capital Firms (number) 1.89 11.45 
Number of Colleges, Universities and Professional Schools (number) 1.08 4.86 
Number of General Medical and Surgical Hospitals (number) 1.75 3.70 
Average Wage per Job (in $1000) 27.05 5.79 
Percent of Persons with a College Degree (percent) 16.51 7.80 
Property Tax (in $1000) 22.74 23.41 
Crime Index ( index in 100) 35.95 139.73 
Land in Farm Acres (in 1000 acres) 301.14 385.21 
   
Note: 1 text in parenthesis indicates units of measurement. 
 
 The spatial association of R&D firms is tested using a global Moran’s I, which 
measures similarities and dissimilarities in R&D establishments across neighboring 
counties (Anselin, 1995). For the number of R&D establishments, y, Morans’I is: 
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where wij indicates elements of the spatial weight matrix, W (Rook contiguity weight 
matrix) between points i and j, μ the mean of all y observations, and i, j=1,…,n. A 
positive and significant value for Moran’s I indicate positive spatial correlation, showing 
that counties with a high or low number of establishments are similar to their neighboring 
counties. Conversely, a negative and significant value for Moran’s I indicates negative 
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spatial correlation, showing that counties with a high or low number of establishments are 
unlike their neighboring counties (Pacheco and Tyrrell, 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Spatial Distribution of R&D and Testing Laboratories, 2003. 
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Figure 4.2. Top 20 U.S. Counties with R&D and Testing Laboratories, 2003. 
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We calculate Moran’s I for the 2003 number of R&D and testing establishments across 
all contiguous U.S. counties, employing GeoDa, a spatial data analysis software.  The 
Moran’s I statistic is equal to 0.2528, indicating a significant strong positive spatial 
relationship.  However, in the case of uneven spatial clustering, global spatial indicators 
such as Moran’s I are found to be less useful. This resulted in a new general class of local 
spatial indicators such as Local Indicators of Spatial Association (LISA, also known as 
Local Moran), which measures the contribution of individual counties to the global 
Moran’s I statistic (Anselin, 1995).  The LISA statistic is calculated for the ith county as: 
(4.2)    ∑=
j
jijii zwzI  
where wij indicates elements of the spatial weight matrix, W (Rook contiguity weight 
matrix), and zi and zj indicates the standardized number of establishments for county i and 
j, respectively.  The sum of LISAs (∑
i
iI  ) for all observations is proportional to global 
Moran’s I, implying that LISA statistic can be interpreted as indicators of local spatial 
clusters and as diagnostics for local instability (spatial outliers) (Anselin, 1995).  
 Figure 4.3 illustrates the R&D and testing industry clusters produced by LISA. It 
indicates the locations with a significant Local Moran statistic classified by type of 
spatial correlation: (a) high-high association (HH), a county with many R&D and testing 
firms has neighboring counties with many R&D and testing firms; (b) low-low 
association (LL), a county with few R&D and testing firms has neighboring counties with 
few R&D and testing firms; (c) low-high association (LH), a county with few R&D and 
testing firms has neighboring counties with many R&D and testing firms; and (d) high-
low association (HL) , a county with many R&D and testing firms has neighboring 
counties with few R&D and testing firms. The HH and LL locations suggests clustering 
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of similar values (positive spatial correlation), whereas the HL and LH locations indicate 
spatial outliers (negative spatial correlation) (Anselin, 1995). A positive and high 
autocorrelation is found in California, the Northeast, as well as in some of the major 
cities such as Seattle, Portland, Salt Lake City, Phoenix, Denver, Houston, Chicago, 
Detroit, and Miami.   
 
 
 
 
 
 
 
 
Figure 4.3. Local Indicator of Spatial Association (LISA) Cluster Map of R&D and 
Testing Establishments, 2003. 
 
 In addition to the spatial autocorrelation, multivariate spatial correlation is also 
analyzed employing a multivariate Moran’s I statistic. The multivariate spatial correlation 
“centers on the extent to which values of one variable (zk) observed at a given location 
show a systematic (more than likely under spatial randomness) association with another 
variable (zl) observed at the neighboring locations.” (Anselin, Syabri, and Smirnov, 
2002). The multivariate Moran’s I is as follows: 
(4.3)    
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Where n indicates the number of observations, W indicates rook contiguity weight 
matrix, and zk and zl indicate standardized variables with mean zero and standard 
deviation equal to one (Anselin, Syabri, and Smirnov, 2002). Using a similar rationale as 
in the development of LISA, a Multivariate Local Moran Statistic (MLMS) was 
developed by Anselin, Syabri, and Smirnov (2002). This is defined as follows: 
(4.4)    jl
j
ij
i
k
i
kl zwzI ∑=  
where wij indicates elements of the spatial weight matrix, W (Rook contiguity weight 
matrix), and ikz  and 
j
lz  indicates the standardized variables for county i and j, 
respectively.  The MLMS “gives an indication of the degree of linear association 
(positive or negative) between the value for one variable at a given location i and the 
average of another variable at neighboring locations.” (Anselin, Syabri, and Smirnov, 
2002). Similar to LISA, MLMS suggests two classes of positive spatial correlation, or 
spatial clusters (HH and LL), and two classes of negative spatial correlation, or spatial 
outliers (HL and LH) (Anselin, Syabri, and Smirnov, 2002). 
 Since the influence of research universities on the location of the R&D industry is 
of potential interest to the spatial and economic scientists, this study analyzes spatial 
correlation between colleges and spatial lag of the dependent variable (number of R&D 
and testing establishments). The Multivariate Global Moran’s I statistic is equal to 
0.2366, indicating a significant positive spatial relationship between research institutes 
and the location of the R&D industry. The MLMSs cluster map indicates a positive 
spatial correlation mainly in the Northeast, California and some of the major metropolitan 
cities, whereas a negative spatial correlation is indicated in some counties of the West 
and Northeast, and parts of Texas (figure 4.4). Similarly, we analyze the spatial 
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correlation between biotech related manufacturing and R&D firms. The Multivariate 
Global Moran’s I statistic is equal to 0.3055, indicating a significant positive spatial 
relationship between biotech related manufacturing firms and the location of the R&D 
industry. The MLMSs cluster map indicates a positive spatial correlation mainly in the 
Northeast, California and major metropolitan cities (figure 4.5). We further analyze this 
relationship along with the other factors discussed earlier, employing a spatial 
econometric model.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Bivariate LISA Cluster Map of Research Institutes and Spatial Lag of 
R&D and Testing Establishments, 2003. 
 
4.5 Econometric Model  
Most of the previous empirical studies on industry location have employed non-spatial 
econometric models, such as the Ordinary Least Squares (OLS), Poisson, Negative 
Binomial, and Tobit  (for recent exception see Roe, Irwin, and Sharp,2002; Goetz and 
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Rupasingha, 2002; Isik, 2004; and Sambidi and Harrison, 2005). Since the data are 
collected with reference to points in space, employing OLS (and models mentioned 
above) as an econometric tool will produce spatially autocorrelated residuals, resulting in 
biased estimates and all inferences based on the model may be incorrect (Anselin, 1988; 
LeSage, 1999).  
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Bivariate LISA Cluster Map of Manufacturing Firms and Spatial Lag of 
R&D and Testing Establishments, 2003. 
   
 The spatial correlation of OLS residuals (without spatial component) is formally 
tested employing different spatial correlation indices (Morans-I, Wald, Lagrange 
multiplier and the Likelihood ratio test statistic), as suggested by LeSage (1999). All the 
tests indicated the presence of spatially correlated residuals in the regression model 
(Table 4.2). To overcome this problem of spatial autocorrelation, two different 
specifications are available. The two forms of specifications are: 1) a spatial 
autoregressive model (SAR), which is appropriate when spatial dependence exists in the 
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form of a spatially lagged dependent variable, and 2) a spatial error model (SEM), which 
is relevant when the spatial dependence operates through the disturbance term (Anselin 
1988).  The former can be expressed as: 
(4.5)    
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yy
σμ
μβρ ++= XW
 
where y is a n x 1 vector of the dependent variable (the number of R&D and Testing 
laboratories), Wy is a spatially lagged dependent variable for spatial weights matrix W, ρ 
is the scalar for spatial lag coefficient, β is the k x 1 parameter vector, X is the n x k 
matrix of exogenous explanatory variables, μ is an n x 1 vector of normally distributed 
error terms with zero mean and variance σ2. The spatial lag Wy can be considered as a 
spatially weighted average of the R&D and Testing facilities at neighboring counties. 
Ignoring a spatially lagged dependent variable yields inconsistent and biased estimates 
for the parameter coefficients in the model (Anselin et al. 2000). 
Table 4.2. Tests for Spatial Correlation in Residuals of a Regression Model. 
Test Statistics     Value 
Moran’s I Statistic 9.815***
Lagrange Multiplier  92.232***
Likelihood Ratio  81.521***
Wald  1072.053***
Note: *** indicates significance at the 1% level 
 
The second form of spatial dependence, which is often expressed as a spatial 
autoregressive process for the disturbance term is expressed as: 
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where λ is a spatial autoregressive coefficient and μ is is a standard spherical error term. 
Ignoring spatial dependence in the error term does not lead to biased estimates, but the 
estimate of their variance will be biased, leading to erroneous interpretations and wrong 
conclusions (Anselin et al. 2000).  
 If there was evidence indicating spatial dependence in both forms, spatial lag and 
error terms, a more general specification can be employed. This general spatial 
specification is called general spatial model (SAC), which accounts for both the spatially 
lagged term as well as a spatial error structure. 
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 This specification is employed if there is evidence that spatial dependence existed 
in the error structure from a SAR estimation, which is tested by employing a LM-test. 
This study employs a spatial two-stage least squares (spatial 2SLS) estimator to examine 
the factors affecting the location of R&D and testing facilities in the U.S. We use the 
spatial 2SLS estimator in the estimation of this model, since it is robust to possible 
misspecifications and it appropriately accounts for the endogenity of the spatial lag term 
(Anselin 1988; Isik 2004).  Moreover, there is a possibility that some of the other 
variables employed in the model may be influenced by R&D and testing laboratories. For 
example, the existence of a R&D and testing laboratory at a particular region may 
influence the location-decision of a biotech related manufacturing firm in that particular 
region.  The spatial 2SLS also accounts for the possible endogenity of the explanatory 
variables in determining the location of R&D firms. We follow Kelejian and Prucha’s 
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generalized spatial 2SLS procedure for estimating the spatial autoregressive model with 
autoregressive disturbances. The model is estimated employing the MATLAB routines 
provided by LeSage’s econometric toolbox (2005).  
4.6 Results 
Results of the empirical estimation are presented in table 4.3. We follow Goetz et al. 
(2004), in employing the criteria outlined by LeSage (1999) to select the appropriate 
spatial specification for our data. Since the general spatial model (SAC) model accounts  
Table 4.3. Estimates of  Factors Affecting the Location of U.S. R&D and 
Testing Facilities. 
Variable    Coefficient       t-stat 
Constant -14.2770*** -4.1780 
Manufacturing firms 1.4832*** 38.8986 
Poverty 0.1528 1.3899 
Population 1.32E-07 0.0350 
Median Housing Value 3.60E-05*** 3.0323 
Unemployment -0.1095 -0.6014 
Median Household Income -0.0001 -0.9406 
Venture Capital 0.3961*** 12.0509 
Colleges 0.9629*** 7.5752 
Hospitals -0.6684*** -3.4984 
Average Wage Per job 0.0003*** 5.0635 
Education 0.2000*** 3.7645 
Property Tax -0.0001*** -4.9191 
Crime Index -0.0002*** -4.2593 
Farm Land -1.54E-06** -1.9380 
Nonmetro-metro 1.0086 1.5784 
lamda          0.4138*** 14.2923 
     
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
        
for both the substantive and nuisance dependence (Anselin et al. 2000), we first estimate 
the SAC model. The estimated SAC model resulted in a negative value for the spatial 
agglomeration parameter (ρ), indicating that there are no spatial effects in the dependent 
variable. However, the SAC model resulted in positive and significant spatial 
autoregressive coefficient (λ), indicating that the spatial dependence exists in the error 
term. Therefore, we employ the SEM specification to estimate the spatial 2SLS model to 
97 
 
analyze the factors affecting the location-decision of R&D and testing firms. The spatial 
2SLS model produced an R-square equal to 0.80 indicating a good-fit for these data. 
Since the spatial autoregressive coefficient (λ) is found to be positive and significant at 
the 1% level, this suggests that inference based on the standard 2SLS specification 
without a spatial correction, is not valid for the data under consideration. This result 
indicates the presence of spatial agglomeration economies for the spatial structure of the 
R&D industry. The positive sign indicates that the spatial distribution of R&D firms is 
positively correlated across counties.  
 Most of the regressors in the estimated model had expected signs and are found to 
be significantly different from zero. The number of manufacturing firms in a given 
county was found to be positive and significant at the 1% level, indicating R&D and 
manufacturing firms’ preference to locate in close proximity of each other. This result is 
in accordance with Gray and Parker (1998) who argued that manufacturing firms that 
produce high-value intermediate active ingredient are located near by R&D firms, since 
the production requires significant input from high-skilled labor.  Similarly, the number 
of research institutes in a given county was also found to be positive and significant at the 
1% level, indicating the significant relationship between R&D firms and research 
institutes. This result is broadly consistent with earlier findings in Audretsch and 
Feldman (1996), Zucker, Darby, and Brewer (1998), and Furman et al. (2006) that 
knowledge spillovers from university research to innovative firms are at work in the 
biotech related R&D industry. Conversely, the number of hospitals in a given county had 
an unexpected negative sign and was found to be significant. 
 The median housing value had a positive and significant impact on the location of 
R&D firms, indicating that firms involved in research activities prefer to locate in 
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counties with well-developed infrastructure and high-standard of living. This result is in 
accordance with the current spatial distribution of R&D firms, which are mainly located 
in the urban areas that are associated with high cost-of-living. Similarly, a county’s 
average hourly wage and education variable, which are considered to be proxies for 
availability of high-skilled labor, are found to be positive and significant at the 1% level. 
A county’s crime rate was found to have negative impact on the location of R&D firms. 
This result indicates that within the metropolitan cities (where most R&D firms are 
located), R&D firms prefer to locate in areas with low crime rate.   
 The property tax variable was found to be negative and significant at the 1% 
level, indicating that R&D firms prefer to locate in counties with low property tax. Since 
the cost associated with the development of an innovative new drug is more than $800 
million (DiMasi, Hansen, and Grabowski 2003; Congressional Budget Office 2006), 
R&D firms prefer to locate in regions that provide R&D tax credits and funding sources 
for their facilities. Similarly, availability of local venture capital was also found to be 
positive and significant, indicating R&D firms’ dependency on local financial sources. 
This result is consistent with earlier findings of Powell, Koput, Bowie, and Smith-Doerr 
(2002) that venture capital firms are an important source of capital for new and small 
R&D firms.  
 The amount of farmland in a given county was found to be negative and 
significant at the 5% level, indicating R&D firms’ preference to locate in urban regions 
with well-developed infrastructure. Generally, counties with large farmland are 
considered to be rural, less populated, with a poor infrastructure, compared to the urban 
counterpart (especially in terms of research universities, good transportation facilities, 
financial resources, specialized intermediate industries, and availability of skilled labor 
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pool). However, the urbanization economies variable (Nonmetro-Metro) was found to be 
insignificant in the location of R&D firms. The reason for this can be that this variable is 
correlated with other explanatory variables, which are picking up its effects.  
4.7 Conclusion 
The hypothesis of spatial agglomeration economies is confirmed for the spatial 
structure of the R&D industry, indicating that R&D firms are positively correlated across 
counties, resulting in clustering of research activities. Proximity to manufacturing firms 
and research universities, and availability of venture capital firms were found to have the 
most significant impact on the location of R&D firms. This indicates that the R&D firms 
prefer to locate in regions where they have a source for financing their business , access 
to research institutes to collaborate with skilled labor and obtain new technology, and 
access to manufacturing firms to produce intermediate active ingredient in large batches 
before it gets commercialized . The significance of both spatial autoregressive parameter 
and the college variable indicate that public as well as private spillovers are at work in the 
R&D industry, resulting in their spatial clustering.  
R&D firms also prefer to locate in counties with a well developed infrastructure. 
This is indicated by the positive and significant estimates of median housing value, 
average wage per job, and education, and a negative and significant estimate of the 
farmland. The significant negative sign associated with property tax estimate indicates 
that in order to attract new R&D firms and develop the existing ones, the state and local 
economic development agencies should provide certain tax credits and business 
incentives.  
These findings may hinder rural areas hopes of attracting R&D firms. However, 
rural areas that are adjacent to major metropolitan cities are still capable of attracting 
manufacturing firms that produce intermediate products and drugs that have achieved 
commercial scale. In order to attract these firms, the rural areas should develop their 
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infrastructure, especially, highway access, housing facilities, and business incentives. 
Thus, the state and local economic development agencies should design strategies based 
on the type of firm they want to attract.  
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CHAPTER 5 
A CRITICAL ANALYSIS OF THE GEOGRAPHICAL DISTRIBUTION OF 
BIOTECH RELATED MANUFACTURING AND R&D FACILITIES IN THE 
UNITED STATES 
 
5.1 Background 
The biotech industry is one of the fastest growing industries in the U.S., increasing sales 
from $7.7 billion in 1994 to $33.3 billion in 2004 (Ernst and Young 2005). According to 
Biotechnology Industry Organization (BIO), in 2003 there were 1,473 biotechnology 
companies in the U.S., employing 198,300 people and spending $17.9 billion on research 
and development. The success of biotech industry is also indicated by the fact that in 
2004, 40 states have adopted strategies to stimulate the growth of biotechnology and 50 
states have technology based economic development initiatives that are available for 
biotech companies (Battelle and State Science and Technology Institute (SSTI) 2004).  A 
survey administered by Grudkova (2001) on 77 local and 36 state economic development 
agencies indicated that 83 percent of the respondents considered biotechnology as one of 
their top two targets for industrial development (Cortright and Mayer 2002). The top five 
states in terms of number of biotech companies are: California (420), Massachusetts 
(193), North Carolina (88), Maryland (84), and New Jersey (77) (figure 5.1; Ernst and 
Young, 2004). The biotech industry is mainly concentrated in nine cities/regions (San 
Francisco Bay Area, Boston/Cambridge, San Diego, Los Angeles, New York, 
Philadelphia, Raleigh-Durham, Seattle and Washington, DC), which account for three-
fourths of the nation’s largest biotechnology firms and for three-fourths of the biotech 
firms formed in the past decade (Cortright and Mayer, 2002).   
 Biotech firms are mainly research and development (R&D) oriented and operate 
in collaboration with research-oriented universities, biomedical research centers, and   
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Figure 5.1 U.S. Biotech Companies by State and Province. 
 
other diversified companies that aid in production and distribution of biotech products. 
The biotech products are related to drugs and pharmaceuticals, agriculture, and 
environment, which aid in improving the quality of health, increasing agricultural 
production, improving the food quality, minimizing environmental hazards and providing 
a cleaner environment. Since different subsectors are involved in the production of 
biotech products, the biotech industry in U.S. doesn’t have a separate NAICS or SIC 
code. However, Battelle and SSTI classified the bioscience into five major subsectors as 
follows: 1. Agricultural Feedstock and Chemicals (AF&C; NAICS: 311221, 311222, 
311223, 325193, 325199, 325221, 325222, 325311, 325312, 325314, 325320, 424910), 
2. Drugs and Pharmaceuticals (D&P; NAICS: 325411, 325412, 325413, 325414), 3. 
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Medicinal Devices and Equipment (MD&E; NAICS: 339111, 339112, 339113, 339114, 
334510, 334516, 334517), 4. Research and Testing (R&T; NAICS: 541380, 541710), and 
5. Academic Health Centers, Research Hospitals, and Research Institutes (Battelle and 
SSTI 2004). In accordance with Battelle and SSTI (2004), the last subsector is not 
included in the study because it cannot be separated from the overall hospital sector. The 
first four subsectors include twenty five industries that are involved in biotechnology 
activities, with total employment of 885,368 jobs across 17,207 establishments (Battelle 
and SSTI 2004). Examples of companies and products produced by each subsector are 
presented in table 1.  For example, some of the products produced by the AF&C 
subsector are: 1. genetically modified high-yield and disease-resistant varieties, 2. ethanol 
and biodiesel fuels, 3. biodegradable materials synthesized from plant-based feedstock 
(Battelle and SSTI 2004).  
 Since biotech activities are performed by several industries belonging to different 
sectors/ subsectors, it is important to analyze location factors specific to a given 
subsector.  For example, industries belonging to the R&T subsector may wish to locate in 
close proximity to research institutes, whereas industries belonging to the AF&C 
subsector may wish to locate in areas with access to farmland. Moreover, variation exists 
in the geographical distribution of the four subsectors. For example, the AF&C subsector 
is found to be most dispersed subsector with 21 states having a specialization1, whereas 
only 8 states have specialization in the D&P subsector (Battelle and SSTI 2004). Several 
studies have empirically examined the location aspects of the U.S. biotech industry; 
however, none of them have simultaneously analyzed location factors specific to a given 
subsector. 
 
1Battelle and SSTI (2004) define regional specialization as regions with Location Quotients (LQ) of 
1.2 or greater. LQ measures the level of employment concentration for a given subsector within a 
state relative to the country (Battelle and SSTI, 2004)
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Table 5.1. Industries in the Bioscience Subsectors 
Categories 
NAICS 
Codes 
Examples of 
Products 
Examples of 
Companies 
Agricultural Feedstock and Chemicals    
Wet Corn Milling 311221 i) Nutritionally 
enhanced, 
genetically 
engineered, insect-
resistant crops 
ii) Ethanol and 
biodiesel fuels 
iii) Biodegradable 
materials 
synthesized from 
plant-based 
feedstock 
BASF, Bayer 
Crop Science, 
Cargill-Dow 
LLC, Dow 
Agrosciences, 
Genencor 
International 
(Bioproducts 
Division), 
Monsanto, and 
Pioneer Hi-Bred 
International. 
Soybean Processing 311222 
Other Oilseed Processing 311223 
Ethyl Alcohol Manufacturing 325193 
All Other Basic Organic Chemical Manufacturing 325199 
Cellulosic Organic Fiber Manufacturing 325221 
Noncellulosic Organic Fiber Manufacturing 325222 
Nitrogenous Fertilizer Manufacturing 325311 
Phosphatic Fertilizer Manufacturing 325312 
Fertilizer (Mixing Only) Manufacturing 325314 
Pesticide and Other Agricultural Chemical Manufacturing 325320 
Farm Supplies Merchant Wholesalers (only seeds) 424910 
  
Drugs and Pharmaceuticals    
Medicinal and Botanical Manufacturing 325411 Vaccines, 
Cancer 
Treatments, 
Herbal 
Supplements and 
Vitamins, 
Tissue and Cell 
Culture Media, 
and Delivery 
Platforms 
Aventis, Biogen 
IDEC, 
Genentech, 
Novartis Animal 
Health Products, 
Ortho Clinical 
Diagnostics, 
Pfizer, and 
Roche 
Centralized 
Diagnostics. 
Pharmaceutical Preparation Manufacturing 325412 
In-Vitro Diagnostic Substance Manufacturing 325413 
Biological Producing (except Diagnostic) Manufacturing 325414 
  
Medical Devices and Equipment    
Electromedical Apparatus Manufacturing 334510 Minimally 
invasive surgical 
equipment 
Systems 
manufactured 
from biomaterials 
Therapeutic 
implantable 
devices 
GE health care, 
Medtronic, 
Smith and 
Nephew, and 
W.L. Gore 
Medical 
Analytical Laboratory Instrument Manufacturing 334516 
Irradiation Apparatus Manufacturing 334517 
Laboratory Apparatus and Furniture Manufacturing 339111 
Surgical and Medical Instrument Manufacturing 339112 
Surgical Appliance and Supplies Manufacturing 339113 
Dental Equipment and Supplies Manufacturing 339114 
  
Research and Testing    
Testing Laboratories 541380 Preclinical drug 
therapeutics 
Human Growth 
Hormones, 
Monoclonal 
antibodies, protein 
receptors, drug 
discovery 
techniques, and 
drug delivery 
technology 
Applied 
Molecular 
Evolution, Inc, 
Charles River 
Laboratories, Isis 
Pharmaceuticals, 
Inc., Sirna 
Therapeutics.  
R&D in Physical, Engineering and Life Sciences 541710 
Source: Battelle and SSTI, 2004. 
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The primary objective of this paper is to identify county level determinants of the 
geographical distribution of the U.S. biotech industry. Specifically, this study analyzes 
the numerous firm-specific, location-specific, and agglomeration factors that affect the 
location, movement and concentration of biotech firms, based on their biotech activities. 
The study utilizes a seemingly unrelated regression model that captures the likelihood of 
contemporaneous correlation between the disturbance terms across equations.  Analyzing 
these factors will aid state and local economic development agencies in designing 
specific strategies to attract biotech firms, based on the functions they perform. 
5.2 Literature Review 
The Biotech industry is defined as “the application of biological knowledge and 
techniques to develop products and services” (BIO, 2005). Goetz and Morgan (1995) 
defined it as “any technique that uses living organisms to make/modify products, improve 
plants or animals, or develop microorganisms for a specific use.” The most critical 
application of biotechnology is seen in the field of medicine, where it is making a 
continuous progress in improving human health and quality of life. One of the important 
applications of biotechnology in medicine is gene therapy, which offers “the potential to 
supply a patient’s cells with healthy copies of missing or defective genes to prevent 
cancer and other diseases” (Ernst and Young 2000).  
Another critical area of biotechnology is agriculture, where it is mainly focused 
on producing genetically modified crop varieties, which are considered to be high-
yielding, disease and environmental stress resistant, with better quality and longer shelf 
life. These genetically modified crop varieties are considered to be environmental 
friendly as they reduce the need for pesticides and herbicides. According to the National 
Center for Food and Agricultural Policy’s (NCFAP) report (Sankula and Blumenthal 
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2004), the U.S. farmers who adopted the 11 biotech crop varieties increased crop yields 
by 5.3 billion pounds, lowered pesticide use by 46.4 million pounds, and saved $1.5 
billion by lowering production costs, which resulted in a net economic impact or savings 
of $1.9 billion (Biotechnology Industry Organization 2005). The U.S. is considered to be 
the global leader in the production of biotech crops, accounting for 58.8% (117.6 million 
acres) of the global area (200 million acres) of biotech crops in 2004 (Council for 
Biotechnology Information 2005). Biotechnology is also widely employed in the 
livestock industry, where it provides tools for improving animal health and increase 
livestock and poultry productivity (BIO 2005).  In the case of food processing industry, 
biotechnology is mainly employed in enzyme production to enhance nutritional value of 
food products. 
 Similar to the differences in functions performed, the four biotech subsectors also 
indicate some differences in their geographical distribution. Stewart (2004) utilized the 
information provided by Battelle and SSTI (2004) and ranked the U.S. states for each of 
the four subsectors based on the LQ (see footnote 1). The top five states for each of the 
four subsectors are as follows: Iowa, South Carolina, Tennessee, West Virginia, and 
Idaho (AF&C); New Jersey, Delaware, Indiana, Connecticut, and North Carolina (D&P); 
Utah, Minnesota, Massachusetts, Delaware, and Indiana (MD&E); and, Delaware, 
Massachusetts, Idaho, Maryland, and California (R&T). Delaware was found to be the 
only state with specialization in all subsectors. Figures 5.2-5.5 presents the top twenty 
U.S. counties with respect to the number of establishments in each of the four subsectors.  
 Only five counties (Cook IL, Los Angeles CA, Maricopa AZ, Orange CA, and San 
Diego CA) are represented among the top twenty counties list for all subsectors.  Figures 
5.6-5.9 presents counties with number of establishments greater than the national average 
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for each of the four subsectors, respectively.  As illustrated in the figures, the AF&C 
subsector is widely distributed (861 counties), compared to the D&P (542 counties), 
MD&E (545 counties), and R&T (408 counties) subsectors. All subsectors, except the 
AF&C, are found to be concentrated in the Northeast, California, and other major 
metropolitan cities.  
Several studies have empirically examined the location aspects of the U.S. biotech 
industry (Goetz and Morgan, 1995; Darby and Zucker, 1996; Gray and Parker, 1998; 
Prevezer, 1998; Lerner and Merges, 1998;; Zucker, Darby, and Brewer, 1998; Brennan, 
Pray and Courtmanche, 1999; Zucker, Darby, and Armstrong, 2003; Xia and Buccola, 
2005).The rationale for concentration of the U.S. biotech industry in California and the 
Northeast has been attributed to proximity to highly research-oriented universities, 
research parks and laboratories, and well-developed infrastructure. Gray and Parker 
(1998) examined the theoretical arguments surrounding the location and organization of 
biotech firms and analyzed the prospects for industrial renewal and regional 
transformation. The authors segregate the U.S. biotech industry into three different 
categories/regions based on the functions performed by biotech firms in those regions. 
 The first category includes mature drug producing regions, such as New York, 
New Jersey, Pennsylvania, Delaware, Illinois, and Indiana. These regions include mature 
pharmaceutical firms that were established prior to the commercialization of 
biotechnology (before 1970s), and are now primarily involved in the manufacturing (53 
%) and marketing (72%) of new drugs. Another category includes emerging drug-
producing regions, such as San Francisco, San Diego, Los Angeles, Seattle, and Boston. 
Firms in these regions were established mainly during and after the commercialization of 
biotechnology, and are primarily involved in R&D activities (82%) for new drugs. A  
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Figure 5.2. Top 20 U.S. Counties with Agricultural Feedstock and Chemical 
Establishments in 2003. 
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Figure 5.3. Top 20 U.S. Counties with Drug and Pharmaceutical Establishments in 
2003. 
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Figure 5. 4. Top 20 U.S. Counties with Medical Devices and Equipment 
Establishments in 2003. 
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Figure 5.5. Top 20 U.S. Counties with R&D and Testing Establishments in 2003. 
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Figure 5.6. Geographical Distribution of Agricultural Feedstock and Chemicals 
Subsector. 
 
 
Figure 5.7. Geographical Distribution of Drugs and Pharmaceuticals Subsector. 
 
 
Mean number of establishments = 3.07 
Mean number of establishments = 0.58
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Figure 5.8. Geographical Distribution of Medical Devices and Equipment Subsector. 
 
 
Figure 5.9. Geographical Distribution of Research and Testing Subsector. 
 
third category includes low-cost periphery regions, such as Puerto Rico, the Southern 
states of the U.S., and other scattered isolated rural areas.  Biotech firms in these regions 
Mean number of establishments = 1.81 
Mean number of establishments = 6.05 
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undertake the production of drug products that have achieved commercial scale and other 
intermediate products (Gray and Parker, 1998). 
Munroe, Craft, and Hutton (2002) conducted a survey of biotech companies in 
three California counties (Alameda, Contra Costa, and Solano). The results indicated that 
proximity to leading research centers (i.e. ready supply of skilled labor, access to ongoing 
research activities, new technology, etc.) as primary determinants for their current 
location. Access to venture capital, a well-trained workforce, space for expansion and 
access to new technology were considered to be the most critical requirements for the 
growth and prosperity of respondents’ business. The results also indicated that state and 
local economic development agencies that provide financial assistance packages (i.e. 
subsidies, tax advantages, loan guarantees, etc.), biotechnology incubators/research parks 
(with appropriate zoning, infrastructure and public transportation), promote public 
awareness and training programs for the workforce. The results also indicated some of 
the respondent’s willingness to locate in regions associated with lower costs (housing, 
space, wages, etc.), less congestion/ commuting, and good incentives such as subsidies 
and tax credits (Munroe, Craft, and Hutton, 2002).                                                       
Goetz and Rupasingha (2002) analyzed the site-specific determinants of U.S. 
high-tech industry, which includes firms that are involved in biotech activities, such as 
drug and pharmaceutical manufacturing firms and R&D services. Their results indicated 
that the availability of an existing high-tech firm, number of college graduates, local 
property taxes, population (urbanization economies), total county income, highway 
access, and county amenity scale have a positive and significant impact on the location of 
high-tech firms. Conversely, a county’s unemployment and unionization rate, per capita 
pollution, and the percentage of black population were found to have a negative and 
significant impact on the high-tech firm’s location. The present article differs from 
118 
 
previous literature in that we examine the differences in factors affecting the location of 
four biotech subsectors simultaneously.  
5.3 Data 
The present study analyzed several categories of variables that are considered to affect 
the location of four biotech subsectors, such as agglomeration factors, infrastructure 
factors, and local economic and socioeconomic factors. County-level data were obtained 
from the 2003 county business patterns (U.S. Census Bureau), Economic Research 
Service, National Agricultural Statistics Service, and U.S. Dept. of Labor. The study 
involve four dependent variables: 1. number of establishments belonging to the AF&C 
subsector, 2. number of establishments belonging to the D&P subsector, 3. number of 
establishments belonging to the MD&E subsector, and 4. number of establishments 
belonging to the R&T subsector.   
A factor that is considered to be a prerequisite for attracting a biotech firm is proximity to 
research institutions. Several studies have analyzed the role of research institutes in the 
development and commercialization of biotechnology (Powell and Brantley, 1992; Darby 
and Zucker, 1996; Zucker, Darby, and Brewer, 1998; Prevezer, 1998; Zucker, Darby, and 
Armstrong, 2003; Dahlander and McKelvey, 2003; Xia and Buccola, 2005). Industry 
funded university research increased from $630 million in 1985 to $2.1 billion in 2004 
(National Science Foundation, 2006), indicating an increasing affiliation between 
university and industry in technology advancement. Some of the primary reasons for this 
collaboration are: access to complementary research activity and human capital, 
increasing commercial opportunities, stringency of patent law and federal policies, and 
the relative decline of public research funding (Santoro and Alok, 1999; Yang and 
Buccola, 2003).  This study includes county-level number of colleges, universities, and 
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professional schools (colleges) as a proxy for the proximity to research institutions and 
assumes it will have a positive effect on the location of four biotech subsectors. County-
level data for this variable was collected from county business patterns (U.S. Census 
Bureau, 1998 and 2003) with 611310 NAICS classification, which includes number of 
colleges, universities, and professional schools. Ongoing research intensity in life 
sciences at research institutions of a particular state is also considered to be a critical 
factor in the location decision of a biotech firm (Zucker, Darby, and Brewer, 1998; 
Munroe, Craft, and Hutton, 2002; Xia and Buccola, 2005).  State level university life 
science R&D expenditures (R&D) is included as a proxy for ongoing research intensity. 
This variable is assumed to have a positive effect on the site-selection of all biotech 
subsectors. State level data for R&D expenditures was collected from National Science 
Foundation. 
 Businesses that provide venture capital are considered to be an important source 
of capital, especially, for new and small firms (Powell, Koput, Bowie, and Smith-Doerr, 
2002).  For a small biotech firm, availability of venture capital in a particular region is as 
important as the strong research capacity of that region. During 2004, venture capital 
accounted for approximately 23.5% of the total financing for the biotech industry. (BIO, 
2005; BioWorld, 2005). Most of the biotech firms are small and operate at a loss, 
spending large amounts of money on research and development for several years before 
earning a profit (Cortright and Mayer, 2002). For example, only 1 in 5,000 potential new 
medicines reach the pharmacy shelf, and that is after 12 to 15 years of R&D with an 
average expenditure of $500 million (California Trade and Commerce Agency, 2001). As 
a result, most of the small biotech firms depend on venture capital funds, on research 
contracts and equity investment from large biotech firms, and on sales of their company 
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stock in public markets (Cortright and Mayer, 2002). Therefore, the availability of local 
venture capital firms (Venture Capital) is hypothesized to have a positive effect on the 
location of all four biotech subsectors (data for county-level number of venture capital 
establishments was collected from county business patterns with 523910 NAICS 
classification).   
  Agriculture is an important component of the biotech industry.  Some studies 
have analyzed issues related exclusively to the spatial distribution of agricultural biotech 
firm location and its relationship with research institutions (Kalaitzandonakes and 
Bjornson, 1997; Graff, 1997; Begemann 1997; Brennan, Pray, and Courtmanche, 1999; 
Sporleder, Moss, and Nickles, 2002; Yang and Buccola, 2003; Sporleder and Moss, 
2004; Xia and Buccola, 2005). Around 13 percent of firms in biotechnology are primarily 
involved in agriculture (Dibner 1995; Graff 1997). According to Ernst and Young (2000), 
in 1999, agricultural biotech firms employed 21,900 workers, generated $2.3 billion in 
revenues and $1.4 billion in personal income for employees and owners. Since biotech 
firms that belong to the AF&C subsector seek applications directed toward agricultural 
production, it is hypothesized that, in order to gain positive economies of scale (low 
transaction costs), agricultural biotechnology prefer to locate in regions with significant 
agricultural production (Farmland) (county level data for farmland was collected from 
U.S. Census of Agriculture). Similarly, since the D&P and MD&E subsectors seek 
applications directed toward human health, we hypothesize that a county with more 
hospitals will have a positive effect on the location of these subsectors. County-level data 
for this variable was collected from county business patterns (U.S. Census Bureau, 1998 
and 2003) with 622110 NAICS classification, which includes number of general medical 
and surgical hospitals.  
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 In terms of conventional location theory, local property taxes (Property Tax) may 
discourage new investment by increasing the costs of production. However, in case of 
high-tech firms (such as the biotech industry), high property taxes are consider to be 
proxies for greater availability or higher quality of local public goods (Goetz and 
Rupasingha), which in turn reflects high standards of living of the local community. 
Therefore, we assume that property taxes are positively correlated with the location of all 
four biotech subsectors (county-level data for property tax collections was obtained from 
the U.S. Census Bureau). Similarly, counties with high unemployment (unemployment), 
which reflect low standards of living of the local community, is considered to have a 
negative effect on the location-decision of biotech firms. County-level data for 
unemployment and poverty rate are collected from Economic Research Service USDA 
and U.S. Bureau of Census, respectively.  In order to measure the impact of urbanization 
economies on the location of biotech firms, we group U.S. counties into Metro (counties 
belonging to rural-urban continuum codes of 1-3) and Non-metro (counties belonging to 
rural-urban continuum codes of 4-9). The study assigns a value of 1 for non-metro 
counties and 0 for metro counties. Since, most of the existing biotech firms are located in 
the metropolitan cities, we hypothesizes that the variable (Metro-Nonmetro) will have a 
negative impact on the location-decision of biotech firms.  
 The impact of labor quality on the location decision of biotech industries is 
measured by county-level average wage per job (Wage) and percentage of persons with a 
college degree (Education) (Zucker, Darby, and Brewer, 1998). Both variables are 
considered to have a positive relationship with the site-selection of all four biotech 
subsectors. County-level data for wage and education are obtained from the Bureau of 
Economic Analysis and Economic Research Service USDA, respectively. Counties with 
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high median household incomes (Income), which represents a high standard of living, are 
considered to have a favorable impact on the biotech firms’ site-selection (county-level 
data for median household income was obtained from Economic Research Service 
USDA).  Similarly, median housing value (Housing Value) is used as a proxy for the 
quality of housing in a given county. It is expected to have a positive impact on the 
location-decision. County-level data for median housing value was obtained from U.S. 
Census Bureau. Table 5.2 presents the descriptive statistics of all the variables included 
in the model. 
Table 5.2. Summary Statistics of Variables.   
Variable Mean Std. Dev. 
Agricultural Feedstock and Chemicals  Establishments (number) 3.07 5.44 
Drugs and Pharmaceuticals Establishments (number) 0.58 2.84 
Medical Devices and Equipment Establishments (number) 1.81 7.95 
Research and Testing Establishments (number) 6.06 28.40 
Nonmetro-Metro (dummy) 0.65 0.48 
Owner-Occupied Housing Units: Median Value (in $1000) 80.93 41.94 
Unemployment Rate (percent) 5.97 1.96 
Median Household Income (in $1000) 36.73 9.28 
Total Number of Venture Capital Firms (number) 1.89 11.45 
Number of Colleges, Universities and Professional Schools (number) 1.08 4.86 
Number of General Medical and Surgical Hospitals (number) 1.75 3.70 
Average Wage per Job (in $1000) 27.05 5.79 
Percent of Persons with a College Degree (percent) 16.51 7.80 
Property Tax (in $1000) 22.74 23.41 
University Life Science R&D Expenditures (in $1000) 563.61 573.18 
Land in Farm Acres (in 1000 acres) 301.14 385.21 
   
 
5.4 Econometric Model 
In order to analyze specific factors affecting the location of each of the four biotech 
subsectors, the present study utilizes seemingly unrelated regression (SUR). In general, 
there could be some non-observed characteristics of locations that are impacting the four 
biotech subsectors. Therefore, the error terms across the four equations may be 
correlated. A separate estimation of each of the four equations will ignore this correlation 
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and may result in inefficient parameter estimates. The SUR model, which estimates the 
four equations simultaneously, follows: 
(5.1)    ,
'
jjjj XY μβ +=  
j= 1 to 4,  
where Yj  is the number of establishments, Xj is the set of explanatory variables, βj is the 
vector of parameters to be estimated for equation j, μj  indicates the error term which 
includes unobservable cross-section specific effects. Breusch-Pagan test (BP) could be 
employed to examine the correlation between residuals from the four equations. Failing 
to reject the BP test of independence, will allow us to estimate each equation separately. 
In addition to the BP test, the study tests for aggregation bias, which test hypothesis about  
the coefficients across equations. It test the hypothesis that the coefficients of a given 
variable across equations are similar indicating that no aggregation bias is present and all 
the four equations can be aggregated into one equation. For example, to test the 
hypothesis that coefficients of variable x2 are similar across four equations, that is β12 = 
β22 = β32 = β42, we may write in the form of linear hypotheses (Zellner 1962) 
β12 - β22 =0 
(5.2)   β12 - β32 =0 
β12 - β42 =0 
5.5 Results 
Tables 5.3 and 5.4 present the parameter estimates and error correlations for each of the 
four subsectors, respectively. The Breusch-Pagan test for the presence of correlation in  
the error terms across equations resulted in a test statistic value of 3874.06 and was found 
to be significant at the 1% level. Hence, the null hypothesis that error correlations are 
zero and each equation is independent is strongly rejected. Similarly, test for aggregation  
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bias rejected the null hypothesis of no aggregation bias based on significant critical chi-
square statistics for individual variables, thus indicating that the four equations SUR is a 
better fit for the data under consideration. Each equation in the SUR model was found to 
be statistically significant as indicated by strong chi-square values, which are found to be 
significant at the 1% level. The goodness of fit measure for each equation in the SUR 
model was indicated by R-square values varying from 0.46 to 0.72. The MD&E subsector 
had the highest R-square value of 0.72.  
Table 5.3. SUR Estimates of Factors Affecting the Location of U.S. Biotech Subsectors 
Variables 
Agriculture 
Feedstock & 
Chemicals 
  Drugs & 
Pharmaceuticals 
Medical devices 
& Equipment 
Research & 
Testing 
Median Housing Value -1.38E-05
***
(-4.51) 
3.11E-06**
(2.18) 
1.34E-05*** 
(4.16) 
4.08E-05***
(3.20) 
Unemployment 0.1570
***
(3.54) 
0.0112 
(0.54) 
0.0539 
(1.15) 
0.2197 
(1.18) 
Median Household Income 0.0001
***
(6.29) 
3.04E-05***
(4.55) 
0.0001*** 
(5.50) 
0.0001*
(1.92) 
Venture Capital 0.0755
***
(7.71) 
0.0043 
(0.93) 
-0.0045 
(-0.43) 
0.4485***
(10.91) 
Colleges 0.5402
***
(22.82) 
0.3343***
(23.63) 
1.0151*** 
(33.06) 
3.3282***
(33.48) 
Hospitals  0.1034
***
(6.66) 
0.4274*** 
(13.58)  
Average Wage Per job -3.25E-05
*
(-1.83) 
8.04E-08 
(0.01) 
-3.57E-06 
(-0.19) 
0.0003***
(4.09) 
Education -0.0090 (-0.62) 
-0.0005 
(-0.08) 
-0.0091 
(-0.59) 
0.2537***
(4.14) 
Property Tax 3.49E-05
***
(9.18) 
-1.59E-06 
(-0.88) 
-1.16E-05*** 
(-2.87) 
-0.0001***
(-3.25) 
Farm Land  1.57E-06
***
(8.32)    
Metro-Nonmetro -0.6904
***
(-3.76) 
0.0490 
(0.57) 
0.0232 
(0.12) 
0.4306 
(0.56) 
Life Science R&D   0.0006
***
(4.52) 
0.0002***
(2.93) 
0.0006*** 
(4.34) 
0.0025***
(4.56) 
Constant -0.8945
***
(-1.39) 
-1.4933***
(-5.03) 
-4.3303*** 
(-6.47) 
-20.2129***
(-7.62) 
R-Square 0.47 0.58 0.72 0.66 
Note: *,**,***  Statistical significance at the 10, 5, and 1% levels, respectively. 
         Values in the parenthesis indicate standard errors.
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 The median housing value had a negative and significant impact on the location 
of biotech firms related to the AF&C subsector, whereas it was found to have a positive 
and significant effect on the location-decision of the other three subsectors. This result is 
in accordance with the fact that most biotech firms are located in major metropolitan 
cities where housing costs are considered to be high. Conversely, biotech firms related to 
agriculture are considered to be located in counties with large farmland where housing  
costs are considered to be low. The unemployment rate variable was found to be 
insignificant in the location-decision of all biotech subsectors, except the AF&C  
subsector, where it was found to be positive and significant at the 1% level. Urbanization 
economies variable (Nonmetro-Metro) was found to be insignificant in the location of all  
four subsectors, except the AF&C subsector. The reason for this can be that this variable 
is correlated with other explanatory variables, which are picking up its effects. The 
variable was found to be negative and significant at the 1% level in the AF&C subsector 
equation. 
  
A county’s median household income, which reflects local standard of living, was found 
to have a positive and significant impact on the location of all four subsectors. This result 
is consistent with previous literature, which indicates biotech firms’ preference for 
locating in regions with a high standard of living and well developed infrastructure. 
Table 5.4. Error Correlations Across Equations. 
 Agriculture Feedstock 
& Chemicals 
Drugs & 
Pharmaceuticals 
Medical devices 
& Equipment 
Research & 
Testing 
Agriculture Feedstock & 
Chemicals 
1.00 0.17 0.19 0.14 
Drugs & Pharmaceuticals 0.17 1.00 0.61 0.57 
Medical devices & 
Equipment 
0.19 0.61 1.00 0.68 
Research & Testing 0.14 0.57 0.68 1.00 
Breusch-Pagan test of independence; chi(2) = 3874.06, Pr = 0.0000 
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Availability of local venture capital was found to be positive and significant in the 
location decision of the AF&C and R&T subsectors, indicating their dependency on local 
financial sources. This result is consistent with earlier findings of Powell, Koput, Bowie, 
and Smith-Doerr (2002) that venture capital firms are an important source of capital for 
new and small biotech firms. The variable that accounts for state level life science 
research and development expenditures was found to be positive and significant in the 
location decision of all four subsectors. This result is in accordance with the current 
spatial concentration of biotech firms in the West and Northeast, which include a greater 
number of states spending large amounts of money on research and development. The 
property tax variable was found to have a negative and significant impact on the location 
of firms related to the R&T and MD&E subsectors, indicating their preference to locate 
in counties with low property tax. Since the cost associated with research and 
development of an innovative new drug is more than $800 million (DiMasi, Hansen, and 
Grabowski 2003; Congressional Budget Office 2006), these firms prefer to locate in 
regions that provide R&D tax credits and funding sources for their facilities. However, 
property tax was found to have an unexpected negative and significant impact on the 
location of firms related to the AF&C subsector.  
 Number of colleges in a given county was found to be one of the most significant 
variables affecting the location of all four subsectors. The variable coefficients range 
between 0.33 (D&P) to 3.33 (R&T). In the case of R&T subsector, the coefficient for 
college variable indicates that as number of colleges in a given county increase by one, 
the number of firms that belongs to the R&T subsector, increase by 3.33. This result is 
broadly consistent with earlier findings in Audretsch and Feldman (1996), Zucker, Darby, 
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and Brewer (1998), and Furman et al. (2006) that knowledge spillovers from university 
research to innovative firms are at work in the biotech related R&D industry.  
 The amount of farmland in a given county was found to be positive and 
significant in the location of AF&C subsector. Agricultural biotech firms’ aim at 
improving agricultural production, as a result of which, they prefer to locate in counties 
with large agricultural production. This will allow firms to utilize local farmland to 
perform the required tests to develop a genetically modified crop variety that can perform 
well under local climatic conditions. Similarly, the D&P and MD&E subsectors prefer to 
locate in close proximity of research hospitals to perform the required tests for 
developing a new drug. This result is indicated by the positive and significant coefficients 
of number of hospitals variable for both the subsectors.   
 A county’s average hourly wage and education variable, which are considered to 
be proxies for availability of high-skilled labor, are found to be positive and significant at 
the 1% level for the R&T subsector. However, the average hourly wage variable was 
found to have a negative and significant impact on the location of AF&C subsector. Since 
the AF&C subsector requires low-skilled labor relative to the R&T subsector, the former 
is considered to pay less, compared to the later.  
5.6 Conclusion 
Biotech firms are mainly research and development (R&D) oriented and operate in 
collaboration with research-oriented universities, biomedical research centers, and  other 
diversified companies that aid in production and distribution of biotech products. Since 
biotech products are related to drugs and pharmaceuticals, agriculture, and environment, 
there is no single NAICS or SIC code for the biotech industry. The study utilizes Battelle 
and SSTI’s (2004) bioscience classification, which include four subsectors that are 
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involved in biotech activities.  The four major subsectors are: 1.agricultutral feedstock 
and chemicals, 2. drugs and pharmaceuticals, 3. medical devices and equipment, and 4. 
research and testing.  
Over the past two decades the U.S. biotech industry has experienced significant 
growth, resulting in an increase in size and number of establishments. Currently, several 
state and local economic development agencies are designing and implementing 
strategies to attract new biotech firms, resulting in stiff competition among and within 
states. As a result of this increasing competition, the U.S. biotech industry is experiencing 
some changes in its geographical distribution. However, only some new state/regions are 
likely to attract biotech firms, as most biotech firms are tending to cluster along existing 
biotech regions. Several studies have analyzed the location aspects of the biotech 
industry, however, our understanding of differences in factors affecting the location of 
each of the four biotech subsectors, is anecdotal. This study employs a seemingly 
unrelated model that simultaneously analyzes factors affecting site-selection of each of 
the four subsectors. 
 Proximity to research institutes to collaborate with skilled labor and obtain new 
technologies, was found to have the most significant impact on the location of R&T 
subsector. Positive and significant estimates of availability of local venture capital firms 
and state-level research and development expenditures indicated the importance of public 
and private financial sources in the location-decision of R&T subsector. This conclusion 
is also indicated by a negative and significant estimate of property tax variable. Firms 
related to the R&T subsector also prefer to locate in a county with access to skilled labor 
and a high standard of living; this is indicated by the positive and significant estimates of 
the median housing value, median household income, average wage, and education 
variables.  
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The D&P and MD&E subsectors prefer to locate in close proximity of research 
institutes and hospitals to access skilled-labor and develop and test the new drugs. Similar 
to the R&T subsector, the two subsectors prefer to locate in counties with high standard 
of living, which is indicated by the positive and significant coefficients associated with 
the median housing value and median household income variables. These findings may 
hinder rural areas hopes of attracting firms related to these three subsectors. However, 
rural areas that are adjacent to major metropolitan cities are still capable of attracting 
manufacturing firms that produce intermediate products and drugs that have achieved 
commercial scale (Gray and Parker 1998) . In order to attract these firms, the rural areas 
should develop their infrastructure, especially, highway access, housing facilities, and 
business incentives. 
Firms belonging to the AF&C subsector prefer to locate in counties with low 
median housing values and average hourly wage, and high unemployment rate. They also 
prefer to locate in counties with large farmland, so that they can improve the quality of 
local crops by developing locally suitable genetically modified crop varieties. However, 
they avoid counties that are highly rural with a poorly developed infrastructure.  These 
results indicate that counties with large farmland can attract agriculture related biotech 
firms provided they develop the necessary infrastructure suitable for them. Thus, the state 
and local economic development agencies should design strategies based on the type of 
firm they want to attract.  
Future research is directed toward analysis factors affecting the location of each 
of the four subsectors by employing spatial econometric models, which account for 
spatial concepts (spatial dependence and heterogeneity) associated with data collected 
from points in space (Anselin 1988) . Furthermore, including county-level variables 
related to the state and local economic development incentives, R&D expenditures, and 
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environmental constraints may further enlighten our understanding of the biotech 
industry location.  
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CHAPTER 6 
SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
6.1 Summary and Conclusions 
The biotech industry is one of the fastest growing industries in the United States. 
Biotechnology is applied in fields as diverse as agriculture, environment, and drugs and 
pharmaceuticals. The biotech industry includes firms involved in R&D services, testing 
laboratories, and manufacturing of biotech products. In addition, the industry collaborates 
with research universities and hospitals for developing new biotech products. Over the 
past two decades the U.S. biotech industry has experienced significant growth, resulting 
in an increase in size and number of establishments. Since most of the state and local 
economic development agencies and research economists believe industrial cluster 
analysis as a policy solution for all regional problems (vom Hofe and Chen 2006). 
Biotechnology cluster development is gaining importance as one of the most vital 
strategies for economic development to enhance regional growth (Grudkova, 2001).  
Several studies have analyzed the location aspects of the biotech industry, however, our 
understanding of the spatial influence on the regional distribution of biotech 
establishments, is anecdotal.  
 To analyze the effects of numerous firm-specific, location-specific, and inter- and 
intra-industry agglomeration factors on the location of the U.S. biotech industry, three 
studies were conducted.  The first study utilized a Bayesian spatial tobit model and 
examined the overall and regional differences in factors affecting the location of the U.S. 
biotech industry. The second study examined the inter- and intra-industry spatial 
association of  biotech related R&D and testing facilities across all contiguous U.S. 
counties employing a Spatial 2SLS model. Finally, the interdependence between the four 
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subsectors of the U.S. biotech industry was analyzed using a Seemingly Unrelated 
Regression model. 
The first study confirmed the hypothesis of spatial agglomeration for the spatial 
structure of the biotech industry, indicating that biotech firms are positively correlated 
across counties, resulting in clustering of biotech production. Availability of venture 
capital firms, research institutions, and hospitals were found to have the most significant 
impact on the location of biotech firms. This indicates that the biotech firms prefers to 
locate in regions where they have a source for financing their business , access to 
research institutes to collaborate with skilled labor and obtain new technology, and access 
to hospitals for research, testing and marketing of new biotech products. Biotech 
companies also prefer to locate in counties with a well developed infrastructure and a 
high standard of living.  
The regional models in this study also shredded some light on the regional 
differences in factors affecting the location of new biotech establishments. Prospective 
biotech firms willing to locate in the West prefer to establish in metro-counties with easy 
access to research institutes and skilled labor pool, and that are associated with low 
median housing values, property taxes, and crime rate. Since the existing biotech firms in 
the Northeast are mainly associated with manufacturing and marketing of biotech 
products, biotech firms preferences are different in the Northeast compared to other 
regions. Biotech firms that are willing to locate in the Northeast prefer counties with easy 
access to funding sources (venture capital firms and state incentives), hospitals for 
research, testing and marketing of new biotech products, and the ones that are associated 
with low median housing value and property tax. 
Spatial clustering of biotech research and testing activities was confirmed in the 
second study. Proximity to manufacturing firms and research universities, and availability 
of venture capital firms were found to have the most significant impact on the location of 
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R&D and testing facilities. The significance of both spatial agglomeration economies and 
research institutes indicate that public as well as private spillovers are at work in the 
R&D and testing industry, resulting in their spatial clustering. The significant negative 
sign associated with property tax estimate indicates that in order to attract new R&D and 
testing firms and develop the existing ones, the state and local economic development 
agencies should provide certain tax credits and business incentives.   
The third study, which analyzed factors affecting the location of four subsectors 
simultaneously, indicated that firms belonging to the agricultural feedstock and chemicals 
subsector prefer to locate in counties with low median housing values and average hourly 
wage, and high unemployment rate. They also prefer to locate in counties with large 
farmland, so that they can improve the quality of local crops by developing locally 
suitable genetically modified crop varieties. However, they avoid counties that are highly 
rural with a poorly developed infrastructure.  These results indicate that counties with 
large farmland can attract agriculture related biotech firms provided they develop the 
necessary infrastructure suitable for them. Conversely, the drug and pharmaceuticals, and 
medical devices and equipment subsectors prefer to locate in close proximity of research 
institutes and hospitals to access skilled-labor and develop and test the new drugs. Similar 
to the research and testing subsector, the two subsectors prefer to locate in counties with 
high standard of living, which is indicated by the positive and significant coefficients 
associated with the median housing value and median household income variables. These 
findings may hinder rural areas hopes of attracting firms related to these three subsectors. 
However, rural areas that are adjacent to major metropolitan cities are still capable of 
attracting manufacturing firms that produce intermediate products and drugs that have 
achieved commercial scale (Gray and Parker 1998) . In order to attract these firms, the 
rural areas should develop their infrastructure, especially, highway access, housing 
facilities, and provide business incentives. Thus, the state and local economic 
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development agencies should design strategies based on the type of firm they want to 
attract. 
One of the limitations of this research is that information related to the extent of 
biotech activities (direct or indirect) performed by each establishment (dependent 
variable) included in the model is unknown. The study assumes that all establishments 
included the model (dependent variable) perform biotech activities at the same level and 
they are all of same size.  
6.2 Future Research 
Future research is directed toward simultaneous analysis of factor affecting the 
location of each of the four subsectors by employing spatial econometric models, which 
account for spatial concepts (spatial dependence and heterogeneity) associated with data 
collected from points in space (Anselin 1988) . Furthermore, including county-level 
variables related to the state and local economic development incentives, R&D 
expenditures, and environmental constraints may further enlighten our understanding of 
the biotech industry location.  
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